Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
11/2010 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
11/25/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100298202 - Bri polypeptides and reducing ab aggregation: This document relates to methods and materials for reducing Aβ aggregation. For example, methods and materials related to the use of BRI polypeptides (e.g., BRI2 polypeptides) and fragments of BRI polypeptides (e.g., a BRI23 polypeptide) to reduce Aβ aggregation in mammals are provided.... Agent: Fish & Richardson P.C.

20100298200 - Compounds and assays for controlling wnt activity: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In... Agent: Enzo Biochem, Inc.

20100298204 - Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast: Disclosed is an osteoblast differentiation promoting and osteoclast differentiation inhibiting agent which comprises a milk protein fraction having the following characteristics (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of... Agent: Greenblum & Bernstein, P.L.C

20100298201 - Peptidomimetic macrocycles with improved properties: The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100298203 - Sdf-i-based glycosaminoglycan antagonists and methods of using same: The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer.... Agent: Loza & Loza LLP

20100298205 - Methods and compositions for the treatment of conditions related to gastric acid secretion: e

20100298206 - Hybrid oligomers, their preparation process and pharmaceutical compositions containing them: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates... Agent: Mccarter & English, LLP Hartford Cityplace I

20100298207 - Pesticidal proteins and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100298208 - Biofilm prevention using lactoferrin: This invention relates to methods and compositions capable of inhibiting biofilm formation. Specifically, provided herein are methods and compositions using Lactoferrin for the inhibition of biofilm formation.... Agent: Pearl Cohen Zedek Latzer, LLP

20100298209 - Compounds for preventing or treating a viral infection: i

20100298210 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.... Agent: Merck

20100298211 - Axmi-001, axmi-002, axmi-030, axmi-035, and axmi-045: toxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Bayer Cropscience Lp Athenix Corporation

20100298212 - Modified insulin polypeptides and their uses: Modified insulin polypeptides and their uses thereof are provided... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20100298213 - Pharmaceutically active insulin receptor-modulating molecules: The invention described herein provides novel pharmaceutically active molecules (including novel peptide derivatives and peptides) that bind to an insulin receptor; compositions comprising such molecules; methods of modulating insulin receptor activity comprising the delivery of such molecules and related insulin-binding molecules (e.g., in the context of treating and/or preventing insulin... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100298216 - Casein derived peptides and uses thereof in therapy: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the oS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and... Agent: Dr. D. Graeser Ltd.

20100298215 - Synthetic apolipoprotein e mimicking polypeptides and methods of use: The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed.... Agent: Ballard Spahr LLP

20100298214 - Treatment of autoimmune disease: The present invention provides compositions, systems, and methods for identifying a patient suffering from and/or susceptible to autoimmune disease who might be likely to respond to treatment with CXCL12 and/or CXCR4 antagonists. The present invention provides novel CXCL12 and/or CXCR4 antagonists, methods of identifying novel CXCL12 and/or CXCR4 antagonists, and... Agent: Choate, Hall & Stewart LLP

20100298217 - Csf-1r mutants: Provided are mutant class III receptor tyrosine kinases (RTKIII) comprising a mutation at the amino acid residue corresponding to the conserved cysteine at residue 432 (C432) or 439 (C439) of a mouse colony-stimulating factor (1) receptor (CSF-IR) precursor having the amino acid sequence of SEQ ID NO: 1, where the... Agent: Amster, Rothstein & Ebenstein LLP

20100298218 - Single branch heparin-binding growth factor analogs: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of... Agent: Peacock Myers, P.C.

20100298219 - Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds: The present invention is directed to the use of tissue protective compounds for the prevention, treatment, amelioration or management of cancer, neoplastic diseases, their symptoms and side-effects associated with the treatment of these indications, i.e. chemotherapy or radiation therapy. In particular, these compounds may be chemically modified erythropoietin peptides or... Agent: Jones Day

20100298220 - Fibroblast growth factor mutants having improved functional half-life and methods of their use: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid... Agent: Vedder Price, PC

20100298221 - 2-phenoxy nicotine acid derivative and use thereof: The present invention relates to novel 2-phenoxy-6-phenyl- and 2-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially... Agent: Barbara A. Shimei Director, Patents & Licensing

20100298222 - Use of an agent that restores tissue perfusion and oxygenation: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100298223 - Fibrinogen for treatment of bleeding in trauma and platelet disorders: The present invention relates generally to use of fibrinogen to prevent or treat excessive bleeding in pre-hospital and hospital settings. In particular, the present invention relates to methods for treating bleeding using fibrinogen in individuals suffering from traumatic hemorrhages in pre-hospital settings and in individuals having thrombocytopenia or qualitative platelet... Agent: Fennemore Craig

20100298224 - Use of mutated antithrombins for treating or preventing coagulation disorders: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.... Agent: Young & Thompson

20100298225 - Peptide gap junction modulators: Disclosed are peptides that facilitate the intercellular communication mediated by gap junctions. The invention has a wide spectrum of useful applications including use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC).... Agent: Clark & Elbing LLP

20100298226 - Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100298227 - treatment of autoimmune conditions with copolymer 1 and related copolymers: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one... Agent: John P. White Cooper & Dunham LLP

20100298228 - Bone-reinforcing food material: Disclosed is a bone-reinforcing agent which comprises a milk protein fraction having the following properties (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 6,000 to 150,000 Daltons; (3) the... Agent: Greenblum & Bernstein, P.L.C

20100298229 - Osteoprotegerin: The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and... Agent: Amgen Inc.

20100298230 - Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as... Agent: Zymogenetics, Inc. Intellectual Property Department

20100298231 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298233 - Compositions and methods related to profiling a plurality of cells based on peptide binding: Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or... Agent: Fulbright & Jaworski L.L.P.

20100298232 - Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof: The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in... Agent: Klauber & Jackson

20100298234 - Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient: The present inventors discovered that the neuromedin U receptor 2 (FM4) molecule is highly expressed in cancer cells such as pancreatic cancer cells. When the present inventors measured the proliferation-suppressing effect of ligands of this molecule against cancer cells, the ligands were found to have cancer cell proliferation-suppressing effects. The... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100298235 - Epithelial cell growth promoter: It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horny layer to thereby reach the desired target... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100298236 - Soluble gp130 muteins with improved binding activity: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding... Agent: Merchant & Gould PC

20100298237 - Use of hdac inhibitors for treatment of cardiac rhythm disorders: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).... Agent: Pearl Cohen Zedek Latzer, LLP

20100298238 - Nontoxic shiga-like toxin mutant compositions and methods: Disclosed are nontoxic mutants of Shiga-like toxin (Stx1 or Stx2), nucleic acids encoding them, compositions containing the mutants and methods of using the mutants in connection with hemolytic euremic syndrome (HUS). Also disclosed are methods of treating HUS using L3 protein fragments, the nontoxic Stx1 or Stx2 mutants, or combinations... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100298239 - Peptide with multiple epitopes: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100298240 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298241 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298242 - Masking the taste of compositons containing salt: The invention relates to the use of sweeteners for masking the salty taste of compositions as well as compositions containing salt and defined sweeteners, the amount of sweeteners being suitable for masking the salty taste of the composition.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100298243 - Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions: The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100298244 - Composition for the prevention and the treatment of helicobacter pylori infection: The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for Helicobacter Pylori infection. This composition inhibits growth of Helicobacter pylori, and can increase the antioxidant activity of gastric mucosal cells through reducing the production of O2.−, H2O2 and NO, and decreasing... Agent: Wpat, PC Intellectual Property Attorneys

20100298245 - Pharmaceutical composition for the treatment of il-8 mediated diseases: A compound of formula (I) can be used for the preparation of a pharmaceutical composition for the treatment, diagnosis or prophylaxis of Interleukin-8 related to viral infections.... Agent: J.a. Lindeman & Co. PLLC

20100298246 - Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same: c

20100298247 - Pesticide compositions exhibiting enhanced activity: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one proteinaceous material and at least one polymeric material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having... Agent: Kevin J. Huser Krieg Devault LLP

20100298248 - Biologically active macrolides, compositions, and uses thereof: The present invention provides a compound of the formula (I) or (II, wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or... Agent: Leydig, Voit & Mayer, Ltd.

20100298250 - Compositions and methods for extracting and using phytochemicals for the treatment of influenza: Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition... Agent: Dalina Pasadena

20100298249 - Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100298251 - Wound-healing agent containing momordicae semen extract: The present invention relates to Momordicae semen extract having wound-healing efficiencies. In particular, the present invention relates to a wound-healing topical transdermal agent comprising an active ingredient of Momordicae semen extract, which is capable of reducing the time required for the closure and treatment of wounds as confirmed in skin-wound... Agent: Frommer Lawrence & Haug

20100298252 - Methods and compositions for ophthalmic treatment of fungal and bacterial infections: The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent, and an antimicrobial agent.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100298253 - Pharmaceutical compositions comprising forms of 5-azacytidine: e

20100298407 - Compositions and methods featuring micronas for treating neoplasia: The invention provides compositions and methods for the treatment of a neoplasia. The methods of the invention involve expressing a microRNA usually repressed by Myc in a cell of a subject diagnosed as having a neoplasia.... Agent: Edwards Angell Palmer & Dodge LLP

20100298405 - Compositions and methods for inhibiting expression of huntingtin gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The... Agent: Alnylam/fenwick

20100298409 - Compositions comprising stat3 sirna and methods of use thereof: The present invention provides nucleic acid molecules that inhibit STAT3 expression. Methods of using the nucleic acid molecules are also provided.... Agent: Seed Intellectual Property Law Group PLLC

20100298412 - Disulfide chemotherapeutic agents and methods of use thereof: Compositions and methods for the treatment of cancer are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100298411 - Lipid-modified double-stranded rna having potent rna interference effect: An object of the present invention is to provide a novel double-stranded RNA that has high nuclease resistance and high cellular uptake efficiency, and that is capable of producing an excellent RNA interference effect. The present invention provides a lipid-modified double-stranded RNA comprising a sense strand having a nucleotide sequence... Agent: Sughrue Mion, PLLC

20100298406 - Method of suppressing tumour growth: A method of suppressing undesirable cell proliferation, such as tumour growth, is provided comprising the step of increasing the level of PCL2 in target cells.... Agent: Valentine A Cottrill Susan Tandan

20100298410 - Micromirs: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100298403 - Modified poly(propylene-imine) dendrimers and their use as transfection agents for amionic bioactive factors ( as amended: e

20100298408 - Oligonucleotide compositions with enhanced efficiency: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide... Agent: Life Technologies Corporation C/o Intellevate

20100298404 - Translocation and mutant ros kinase in human non-small cell lung carcinoma: In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3h protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion... Agent: Nancy Chiu Wilker, Ph.d. Chief Intellectual Property Counsel

20100298419 - Antibiotic-free plasmid: The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous... Agent: Judy Jarecki-black Ph.d., J.d.

20100298418 - Assay for measuring plasma fgl-2 and methods and uses thereof: The disclosure relates to methods for identifying a subject having elevated FGL2 plasma levels, the method comprising the step of assaying a plasma sample from the subject to determine a level of FGL2, wherein a level above control indicates the subject has elevated FGL2 levels. Diagnostic methods, methods of monitoring... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100298420 - Compositions and methods for intracellular delivery: The invention relates to intracellular delivery of alcoholic lipid compositions for medical, cosmetic, research, diagnostic, veterinary, agriculture or pharmaceutical use containing phospholipid(s), ethanol (or other C2-C4 such volatile alcohols), water, at least one active molecule, optional addition of glycols and/or other additions for delivery to cells of an entrapped, attached,... Agent: Leydig Voit & Mayer, Ltd

20100298414 - Development of a preventive vaccine for filovirus infection in primates: The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.... Agent: Townsend And Townsend And Crew, LLP

20100298417 - Modulation of factor 7 expression: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and... Agent: Knobbe, Martens, Olson & Bear, LLP

20100298416 - Preventing hyaluronan-mediated tumorigenetic mechanisms using intronic rnas: Patterns of microRNA (miRNA) expression are correlated to the degrees of tumor cell differentiation in human prostate cancer. MiRNAs can complementarily bind to either oncogenes or tumor suppressor genes, resulting in targeted gene silencing and thus changes of cellular tumorigenecity. Using miRNA microarray analysis, 8 down-regulated and 3 up-regulated known... Agent: Hogan Lovells US LLP

20100298415 - Targeted schiff base complexes: The present invention provides targeted Schiff base complexes. In particular the present invention provides biopolymer targeted transition metal complexes configured to inhibit the activity of targeted proteins, methods of synthesis thereof, and pharmaceutical compositions and uses thereof.... Agent: Casimir Jones, S.c.

20100298413 - Use of oligotide for the treatment of renal diseases: The present study has demonstrated that heparanase expression and activity was increased in human microvascular endothelial cells and rat kidney epithelial cells growing under hyperglycemia condition, as found in diabetic nephropathy disease. Oligotide was able to: —downregulate the heparanase gene expression; —downregulate the cell surface protein expression; —decrease the heparanase... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20100298254 - Organ arrest, protection and preservation: e

20100298255 - Methods for providing personalized medicine test ex vivo for hematological neoplasms: Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using... Agent: Knobbe Martens Olson & Bear LLP

20100298256 - Antiviral compounds: Lipid-modified phosphodiester nucleoside prodrugs are described herein. The prodrugs can be used to treat viral infections and cancer.... Agent: Ecotech Law Group, P.C.

20100298257 - Nucleoside phosphoramidates: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.... Agent: Merchant & Gould PC

20100298258 - Analgesic compositions: Embodiments of the invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation in mammals, including humans, by administering compositions comprising i) an effective amount of an analgesic having an optional anti-inflammatory effect; (ii) an amount of caffeine effective in enhancement of pain relief; and, (iii)... Agent: Ross T. Robinson Winstead PC

20100298259 - Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100298261 - Edible compositions for lowering cholesterol: The present invention is related to improved compositions for reducing serum total and/or LDL cholesterol levels. The compositions are combinations of dietary fibre and plant sterol. The compositions are used as such or more advantageously in food products and comprise one or several fibres, preferably β-glucan, in combination with one... Agent: Arent Fox LLP

20100298260 - Non-anticoagulant polysaccharide compositions: Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.... Agent: Lando & Anastasi, LLP

20100298262 - Process for the ultrapurification of alginates: A process for the ultrapurification of alginates is provided. In particular, the process may be used for microencapsulation in human cell transplants.... Agent: Tutunjian & Bitetto, P.C.

20100298263 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect: p

20100298264 - Biodegradable and water-soluble hemostatic material and a method for preparing the same: A biodegradable and water-soluble hemostatic material is provided. The hemostatic material comprises an oxidized regenerated cellulose salt having a degree of carboxylic acid oxidation not less than 5%, a degree of etherification of 0.2 to 1.2 and a number average molecular weight of 50,000 to 200,000. The hemostatic material according... Agent: Jianq Chyun Intellectual Property Office

20100298265 - Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin: There is described an inclusion complex of raloxifene hydrochloride and β-cyclodextrin in the solid phase having a specific X-ray powder diffraction spectrum. The invention also relates to a process for obtaining the raloxifene hydrochloride inclusion complex with β-cyclodextrin of the invention. The complex of the invention is employed as a... Agent: Kit M. Stetina, Esq. Stetina Brunda Garred & Brucker

20100298266 - Hydroxyethylstarch: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining... Agent: Klein, O'neill & Singh, LLP

20100298267 - Aminopyrimidinamides as pesticides: The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100298268 - Controlled release formulations of levodopa and uses thereof: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and... Agent: Mandel & Adriano

20100298269 - Prodrugs of cgrp receptor antagonists: Disclosed are prodrug compounds of formula (I) (wherein variables R1 and R2 are as described herein) which are analogues of an antagonist of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to... Agent: Merck

20100298271 - Compounds for use in the treatment of cancer: Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y... Agent: Knobbe Martens Olson & Bear LLP

20100298270 - Novel compounds and methods of using them: Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100298272 - Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same: A new anticancer compounds of formula (1) Drugs and pharmaceutical compositions to be used in human or veterinary medicine, which include at least one compound of formula (1). A method of treating and/or preventing cancer in a human or an animal using the compound of formula (1)... Agent: Young & Thompson

20100298273 - Lipid mixture for infant nutrition: The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.... Agent: Reed Smith LLP

20100298274 - Fat containing composition: A composition comprises a fat phase wherein the fat phase comprises: more than 10 wt. % DHA and/or EPA or derivatives thereof; or more than 5 wt. % GLA or a derivative thereof; or more than 10 wt. % of GLA, EPA and/or DHA in total or derivatives thereof; and... Agent: Ryan Kromholz & Manion, S.c.

20100298275 - Methods of and formulations for reducing and inhibiting the growth of the concentration of microbes in water-based fluids and systems used with them: The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use glutaraldehyde and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C1-C3 alkyl- and alkenyltris(hydroxymethyl)phosphonium salts and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100298276 - Thyroid receptor ligands: In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100298277 - Angiotensin ii receptor antagonists: or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, which is useful for treating hypertension.... Agent: Merck

20100298278 - Inhibitors of beta-secretase for the treatment of alzheimer's disease:

20100298279 - Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20100298280 - Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds: The present invention relates to tetranortriterpenoid compounds and pharmaceutical compositions thereof, which are provided for use in the treatment, diagnosis and/or prevention of trinucleotide repeat disorders (like a polyglutamine diseases, e.g Huntingdon's disease), amyloid diseases, neurodegenerative disease, protein misfolding diseases or tumors. The tetranortriterpenoid compounds of the present invention are... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100298281 - Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer: The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.... Agent: Licata & Tyrrell P.C.

20100298283 - Pharmaceutical composition for enhancing immunity, and extract of poria: A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The extract contains 5-60% of the lanostane compounds by weight of... Agent: Bacon & Thomas, PLLC

20100298282 - Treatment of ocular conditions and the side-effects of glucocorticoids: A compound having glucocorticoid receptor (GR) antagonist activity and a clogP value of less than 5 is useful for the treatment of an ocular condition. Further, a compound having glucocorticoid receptor (GR) antagonist activity is useful, for the treatment of a patient exhibiting side-effects of the administration of a glucocorticosteroid,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100298285 - Biclycloheteroaryl compounds as p2x7 modulators and uses thereof: Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Klauber & Jackson

20100298286 - Organic compounds: c

20100298287 - Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them: There is provided a compound of the formula (I′): wherein X is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to -8-membered heterocyclic ring, etc., and each of Y1,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100298284 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.... Agent: Portola Pharmaceuticals, Inc. C/o Swiss Tanner, P.C.

20100298290 - Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture: v

20100298288 - Cetp inhibitors derived from benzoxazole arylamides: Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease,... Agent: Merck

20100298291 - Fused bicyclic-substituted amines as histamine-3 receptor ligands: m

20100298289 - Heterobicyclic compounds as histamine h4-receptor antagonists: The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100298293 - Substituted oxazolidinones and their use: The invention relates to novel substituted oxazolidinones, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases, and to the use thereof for producing medicaments for treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100298292 - Modulators of 5-ht receptors and methods of use thereof: e

20100298294 - Ketone bodies and ketone body esters as blood lipid lowering agents: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units... Agent: Cook Alex Ltd

20100298295 - 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase... Agent: Genomics Institute Of The Novartis Research Foundation

20100298296 - Oligomer-tricyclic conjugates: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the... Agent: Nektar Therapeutics

20100298298 - Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof: The invention relates to quinazolinedione derivatives, processes for the preparation thereof and their therapeutic applications.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100298297 - Tetrahydropyridothienopyrimidine compounds and methods of use thereof: e

20100298299 - non-peptide derivatives as bradykinin b1 antagonists: The present invention relates to new non-peptide derivatives of formula (I), wherein R1-R5, Q and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, to pharmacological compositions... Agent: Fish & Richardson P.C.

20100298303 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.... Agent: Merck

20100298302 - Novel protein kinase modulators: The invention provides compounds that inhibit selected kinases (Pim, Flt and/or CK2 kinases) and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain infections and immunological disorders.... Agent: Cooley LLP Attn: Patent Group

20100298301 - Oxazole tyrosine kinase inhibitors: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1... Agent: Heslin Rothenberg Farley & Mesiti PC

20100298300 - Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases: e

20100298304 - Diagnosis and treatment of autism spectrum disorders: The invention relates to methods for diagnosis and treatment of autism spectrum disorders, particularly for autism spectrum disorders characterized by increased head size (circumference) and deficits in social behavior.... Agent: Wolf Greenfield & Sacks, P.C.

20100298306 - (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease: e

20100298307 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the... Agent: Birch Stewart Kolasch & Birch

20100298305 - Tizanidine for the treatment of post-traumatic stress disorder and nightmares: Disclosed herein are methods of treating a psychiatric disorder, such as a sleep disorder, an anxiety disorder, a mood disorder or a perceptual disturbance. In one example, a method of treating a sleep disorder or anxiety disorder includes selecting a subject with a sleep disturbance or anxiety disorder in the... Agent: Klarquist Sparkman, LLP

20100298308 - Compositions and methods for bone formation and remodeling: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated... Agent: Enzo Biochem, Inc.

20100298309 - Tricyclic triazolic compounds: The present invention relates to new tricyclic triazolic compounds having a high affinity for sigma-1 receptor as well as to the process for the preparation thereof, to composition comprising them and to their use as medicaments according to compounds of formula (I), Wherein R1 and R2 are as defined in... Agent: Ostrolenk Faber Gerb & Soffen

20100298311 - Tetrahydronaphthalene derivates, process for preparing them and their use as antiinflammatory agents: e

20100298310 - Thiazole derivatives as kinase inhibitors: A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100298312 - Substituted pyrimidinyl-amines as protein kinase inhibitors: The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.... Agent: Darby & Darby P.C.

20100298313 - Method of using imidazolothiazole compounds for the treatment of disease: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.... Agent: Jones Day

20100298315 - Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmnaceutical compositions and novel use as met inhibitors: m

20100298314 - Novel jnk inhibitors: Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.... Agent: Merck Patent Department (k-6-1, 1990)

20100298316 - Benzothiazoles having histamine h3 receptor activity: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings,! of the general formula (1): having histamine H3 antagonistic activity can be used in pharmaceutical compositions.... Agent: High Point Pharmaceuticals, LLC

20100298317 - Method of treating polycystic kidney diseases with ceramide derivatives: A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100298318 - Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease,... Agent: Wilmerhale/dc

20100298320 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use: The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of... Agent: Swanson & Bratschun, L.L.C.

20100298319 - Pyrimidine substituted purine derivatives: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as... Agent: Connolly Bove Lodge & Hutz LLP

20100298321 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.... Agent: Jones Day

20100298322 - Quinazolines and related heterocyclic compounds, and their therapeutic use: A compound of the formula (I) wherein X is CR1 or N; Y is CR3 or N; R1, R3, R4, R5 and R6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R7 is a heterocyclic group including one or more... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100298323 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Jones Day

20100298324 - Prolyl hydroxylase inhibitors: s

20100298325 - Pyridine derivatives for the treatment of amyloid-related diseases: a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m=0-1, n=0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen halogen, CF3, CN, OR8,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100298326 - Carboxamide compounds and their use as calpain inhibitors: c

20100298327 - Aprepitant polymorph mixtures: Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific Hweight ratios of the forms.... Agent: Dr. Reddy''s Laboratories, Inc.

20100298328 - 1-heterocyclylamino-2-hydroxy-3-amino-omega-arylalkanes: 1-Heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100298329 - Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers: The invention provides compositions and methods for treating cancer. Aspects of the invention relate to therapeutic compositions comprising tolperisone and related compounds. Aspects of the invention relate to methods and compositions for treating Ras-associated cancers.... Agent: Wolf Greenfield & Sacks, P.C.

20100298330 - Haloallylamine inhibitors of ssao/vap-1 and uses therefor: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment... Agent: Foley & Lardner LLP

20100298331 - Triazinone and diazinone derivatives useful as hsp90 inhibitors: The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in... Agent: Foley & Lardner LLP

20100298332 - Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands: e

20100298333 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Fish & Richardson P.C.

20100298334 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors: e

20100298335 - Preparations and methods for ameliorating or reducing presbyopia: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase... Agent: Brinks, Hofer, Gilson & Lione

20100298338 - Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit: The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.... Agent: Novartis Corporate Intellectual Property

20100298337 - Organic compounds: Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20100298336 - Pyrimidines as novel therapeutic agents: The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a... Agent: Clark & Elbing LLP

20100298339 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such... Agent: Swanson & Bratschun, L.L.C.

20100298340 - Thiazol-guanidine derivatives useful as a (beta)-related pathologies: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100298341 - Glycine transporter-1 inhibitors: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also... Agent: Amgen Inc.

20100298343 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Glaxosmithkline Global Patents

20100298342 - Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising... Agent: Merck

20100298346 - Nitrogenous heterocyclic compounds with insecticidal activity, and the preparation and use thereof: The present invention relates to nitro-containing heterocyclic or ring-opening nitrogenous compounds of formula (A), wherein R1, R2, R3, R4, R5, Y, Z, and W are as defined in the specification. The present invention discloses the preparation and the uses of a novel insecticide. Said compound and the derivatives thereof have... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100298344 - Polycationic compounds and uses thereof: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally,... Agent: Pepper Hamilton LLP

20100298345 - Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer: Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a... Agent: Techlaw LLP

20100298348 - Method of decreasing ubiquitylated protein levels: The present invention provides a method of decreasing the level of ubiquitylated protein in a subject, the method comprising administering a heterocyclic compound disclosed herein or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100298347 - Substituted 2-naphthoic acids as antagonists of gpr105 activity: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions... Agent: Merck

20100298349 - Thienopyrimidine compounds and compositions: Compounds of formula (I) are A2B wherein R1 and R2 are independently selected from hydrogen, or optionally substituted CrC6 alkyl, C1-C6alkoxy-(C1-C6)-alkyl, C3-C8 cycloalkyl, aryl, heteroaryl, aryl-(C1-C6)-alkyl, or heteroaryl-(C1-C6) -alkyl; or R−1 and R2 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or... Agent: Banner & Witcoff, Ltd.

20100298350 - Triazolo[4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms: The invention provides triazolo [4,5-d]pyrimidine compounds, acting as P2T(P2Y12)receptor antagonists. The compounds are useful for the treatment or prevention of abdominal aortic aneurysms.... Agent: Pepper Hamilton LLP

20100298351 - Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti-cancer agents: The invention relates to substituted pyrazolo[3,4-d]pyrimidine derivatives of the Formula-(I), or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted pyrazolo[3,4-d]pyrimidine derivatives, to... Agent: Merchant & Gould PC

20100298354 - Crystalline form of abacavir that is essentially free of solvent: Crystalline form of abacavir that is essentially free of solvent of formula (I), in particular crystalline Form I, and its preparation process which comprises the following steps: a) crystallizing abacavir from a solution of said compound in a (C1-C4)-alcohol, dichloromethane, acetonitrile/water, or mixtures thereof; b) isolating the crystalline form of... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20100298353 - Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment: A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day.... Agent: Novartis Corporate Intellectual Property

20100298352 - Small molecule inhibitors of cancer stem cells: A method of inhibiting a carcinoma in a subject, comprising administering to the subject at least one therapeutic agent that selectively targets carcinoma stem cells. Illustrative carcinoma stem cell-selective therapeutic agents include CGP74514A, rottlerin, and A-77636.... Agent: Klarquist Sparkman, LLP

20100298355 - 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors: The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20100298356 - Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides: Compounds of the general formula (I), wherein the substituents are as defined in claim 1, are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100298357 - Maleate salts of a quinazoline derivative useful as an antiangiogenic agent: The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in... Agent: Morgan Lewis & Bockius LLP

20100298358 - Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors: and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and/or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases,... Agent: Eckert Seamans Cherin & Mellott

20100298359 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein R2 is a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).... Agent: Merck Patent Department (k-6-1, 1990)

20100298360 - Small molecule inhibitors of pdz interactions: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.... Agent: Tamara A. Kale Fulbright & Jaworski L.L.P.

20100298361 - Alkylthio pyrimidines as crth2 antagonists: Provided herein are alkylthio substituted pyrimidine compounds having CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity, useful for the treatment or prophylaxis of diseases associated with CRTH2 activity, including the treatment of allergic diseases, eosinophil-related diseases and basophil-related diseases.... Agent: Jones Day

20100298362 - Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester: The present invention is directed to a process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.... Agent: Philip S. Johnson Johnson & Johnson

20100298363 - Use of carboxyamidotriazole (cai) orotate in macular degeneration: Method and composition of Carboxyamidotriazole orotate for treating age-related macular degeneration and other angiogenesis-dependent diseases.... Agent: Rashida A. Karmali

20100298364 - salts 756: The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.... Agent: Morgan Lewis & Bockius LLP

20100298366 - Chemokine receptor binding compounds: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).... Agent: Morrison & Foerster LLP

20100298365 - Topical administration carrier composition and therapeutic formulations comprising same: A topical administration carrier composition including water, glycerin and polysorbate, suitable for use in formulations with active ingredient compositions containing active ingredients such as minoxidil that are susceptible to systemic penetration, and solvents that are susceptible to evaporative loss, when the active ingredient composition is topically applied to the body.... Agent: Intellectual Property / Technology Law

20100298367 - Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders: t

20100298368 - Antagonists of pgd2 receptors: Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated... Agent: Wilson, Sonsini, Goodrich & Rosati

20100298369 - Berbamine derivatives: The invention provides novel berbamine derivatives, and compositions or pharmaceutical compositions thereof. These berbamine derivatives have shown higher potency in killing cancer/tumor cells comparing to berbamine, and can be used in cancer/tumor treatments.... Agent: Perkins Coie LLP

20100298370 - Benzothiazolyl thienopyridine derivatives and uses thereof: Novel benzothiazolyl thienopyridine compounds are provided and pharmaceutical compositions comprising benzothiazolyl thienopyridine compounds. The benzothiazolyl thienopyridine compounds are capable of inhibiting the interactions between vascular endothelial growth factor (VEGF) and heparan sulfate glycosaminoglycans (HS-GAGs), and are useful for prevention or treatment of diseases and disorders such as inflammation, autoimmune diseases... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100298371 - Process for preparing chemically and chirally pure solifenacin base and its salts: The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98% purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic... Agent: Renner Kenner Greive Bobak Taylor & Weber

20100298372 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).... Agent: Merck Patent Department (k-6-1, 1990)

20100298374 - Nitrile derivatives and their pharmaceutical use and compositions: i

20100298373 - Oxadiazole derivatives active on sphingosine-1-phosphate (sip): The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100298375 - medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease: The invention relates to a medicament for treating Alzheimer's disease comprising as active ingredients a carbostyril derivative of the general formula: wherein A is a lower alkylene group, R is a cycloalkyl group, the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a double... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100298376 - Use of novel neuroprotective 3-substituted indolone compositions: The present invention provides compositions and methods of synthesizing optionally substituted 3-substituted indolin-2-ones and methods to employ the resultant compounds to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke.... Agent: Chalker Flores, LLP

20100298378 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament: e

20100298377 - Novel substituted indazoles, the preparation thereof and use of same in therapeutics:

20100298379 - Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.... Agent: Birch Stewart Kolasch & Birch

20100298380 - N-aryl-n-piperidin-4-ylmethyl-amide derivatives and thier use as monoamine neurotransmitter re-uptake inhibitors: i

20100298381 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of 5-membered, nitrogen-containing heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention,... Agent: Merck Patent Department (k-6-1, 1990)

20100298382 - Compositions and methods for alleviating depression or improving cognition: This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100298383 - Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20100298384 - Novel oxazolidinone compounds as antiinfective agents: The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents... Agent: Nelson Mullins Riley & Scarborough LLPIPDepartment

20100298385 - Protein kinase inhibitors useful for treatment of cancers: e

20100298386 - Compositions and methods for treating mastitis: The present disclosure relates to compositions that are effective in controlling or in preventing mastitis in an animal. The disclosed compositions comprise a biocidal system, comprising a primary biocide and a preservative component; a nonionic surfactant having an HLB of from about 10 to about (20); an emollient system comprising... Agent: Sutherland Asbill & Brennan LLP

20100298387 - Il-8 receptor antagonists: This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100298388 - Substituted benamidines as antibacterial agents: Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═C(H)— or ═N—; R3 is a radical of formula -(Alk1)m-(Z1)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z1 is —O—, —S—, —S(O)—, —S(O2)—,... Agent: Banner & Witcoff, Ltd.

20100298389 - Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders: The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4′-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100298390 - Inhibition of lethal factor protease activity from anthrax toxin: The present invention provides compounds that efficiently and specifically inhibit lethal factor (LF) protease activity of anthrax toxin.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100298391 - Amide compounds and use thereof for plant disease control: e

20100298392 - Isoindoline derivatives for the treatment of arrhythmias: There is provided compounds of formula I, wherein R1 to R7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.... Agent: Pepper Hamilton LLP

20100298393 - Modulation of growth hormone, dhea, and cortisol with positive modulators of ampa type glutamate receptors: Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the baseline circulatory level of a growth... Agent: Bozicevic, Field & Francis LLP

20100298394 - Antifungal agents as neuroprotectants: Provided herein are compounds, compositions and methods for protecting neuronal and glial cells.... Agent: Edwards Angell Palmer & Dodge LLP

20100298395 - Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same: where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment... Agent: Allergan, Inc.

20100298396 - Manufacture, compositions and uses of coagulation factor viia modulator: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100298397 - Method of treatment of obsessive compulsive disorder with ondansetron: Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI and the ondansetron is then repeated for more than seven... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100298398 - Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells: The present invention provides methods of inhibiting human myeloid leukemia cell growth and proliferation by administering a thrombopoietin receptor agonist (TpoRA), a derivative, or variant thereof, to an individual with AML.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100298399 - Endothelin single nucleotide polymorphisms and methods of predicting b-adrenergic receptor targeting agent efficacy: The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results... Agent: Fulbright & Jaworski L.L.P.

20100298400 - Salts of perindopril: The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts.... Agent: Hovey Williams LLP

20100298401 - Galenical form for the administration of triptans by buccal transmucous means: e

20100298402 - Stilbene derivatives as pstat3/il-6 inhibitors: Described are novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These novel compounds can inhibit pSTAT3/IL-6 and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth... Agent: Oliff & Berridge, PLC

20100298421 - Derivatives of taxol and closely related compounds: A cytotoxic composition in which two moieties are conjugated covalently. A first moiety is a tax moiety, selected from the group consisting of taxanes, taxane derivatives, and or other closely relative compounds. A second moiety is an acid moiety selected from the group consisting of lipoic acid, acetylcysteine, compounds having... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100298422 - Novel polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same: Novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and a method for preparing the same.... Agent: Young & Thompson

20100298423 - Nutraceutical composition from garcinia mangostana: Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in γ-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-α, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic... Agent: Kramer & Amado, P.C.

20100298424 - Method for treating abdominal discomfort: Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders.... Agent: Sughrue Mion, PLLC

20100298425 - Use of tocotrienols for elevating ikbkap gene expression and treating familial dysautonomia: The present invention provides methods for elevating IKBKAP gene expression and the level of functional IKAP protein in cells, which are beneficial to human individual, such as an individual suffering from Familial Dysautonomia, by providing one or more tocotrienols alone or in combination with one or more tocopherols to the... Agent: Scully Scott Murphy & Presser, PC

20100298426 - Therapeutic agent for substance dependence: The present invention provides a therapeutic agent for substance dependence, which prevents relapse/recurrence of compulsive substance-taking behavior based on craving for addictive substances such as stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, cocaine, hemp, cannabis, alcohol, or volatile organic solvents. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100298427 - Anti-inflammatory compositions and their use: wherein the clotted line is an optional bond; R1 is butyl or butyryl if R2 is hydroxyl but is butyl if R2 is hydrogen; or R1 and R2 taken together are 1-butylidene optionally substituted by hydroxyl, methyl, or 3-(α,β-dimethylacrylyloxy)-pentylidenyl; X is a residue selected from the group consisting of X1,... Agent: Nixon & Vanderhye, PC

20100298428 - Continuous administration of dopa decarboxylase inhibitors and compositions for same: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon... Agent: Goodwin Procter LLP Patent Administrator

20100298429 - Continuous administration of dopa decarboxylase inhibitors and compositions for same: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon... Agent: Goodwin Procter LLP Patent Administrator

20100298431 - Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease: A method of treating an individual having Down syndrome or Alzheimer's disease, which entails the step of administering an amount of one or more compounds to the individual which improve cognitive functioning in the individual by increasing hippocampal NE levels.... Agent: Juneau Partners

20100298430 - Prophylactic antistress agent: The present invention relates to a prophylactic antistress agent and a central fatigue improver, which contain chlorogenic acids or pharmaceutically acceptable salts thereof as active ingredients. The present invention makes it possible to prevent and improve mental task fatigue, physical fatigue, central fatigue, central fatigue syndrome, overwork and the like.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100298432 - Cosmetic compositions containing esters of 2-butyloctanol: The invention relates to the use of esters of 2-butyloctanol with C2-36 carboxylic acids or C2-36 dicarboxylic acids in cosmetic and/or pharmaceutical preparations. The compounds are characterised by a particularly light feeling.... Agent: Fox Rothschild LLP

20100298433 - Branched chain fatty acids for prevention or treatment of gastrointestinal disorders: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent 5 or treat the gastrointestinal condition in the subject. The present invention is also... Agent: Nixon Peabody LLP - Patent Group

20100298434 - Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation: There is provided methods for the prevention of dopaminergic cell death for neuroprotection and the prevention or slow down of progression of Parkinson's disease. Particularly, the invention relates to methods for protecting and/or preventing dopaminergic cell death by the administration of a compound or agent inhibiting the translocation of Nur77... Agent: Ogilvy Renault LLP

20100298435 - Stable emulsions of oils in aqueous solutions and methods for producing same: Methods for making highly stable, oxidation-resistant emulsions comprising an oil, an emulsifier, an emulsion stabilizer and water are provided. The invention is particularly well suited for oils that are susceptible to oxidation, such as long chain polyunsaturated fatty acid oils. The resulting emulsion is highly stable and resistant to oxidation,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c

20100298436 - Ep2 agonist from non-prostanoid structures designed as pge2 antagonists: t

20100298437 - Use of citrulline for treating undernutrition conditions: The invention relates to the use of L-citrulline (I) or of one of its pharmaceutically acceptable salts in the preparation of a drug for the treatment of states or undernutrition as linked to a lowering of protein synthesis within the framework of pathologies which do not result from an intestinal... Agent: Young & Thompson

20100298438 - Gene expression profiling of parkinson's disease: The present invention identifies the changes in gene expression associated with Parkinson's Disease by examining multiregional gene expression from normal brain and brain of Parkinson's Disease. The present also identifies the changes in gene expression associated with Parkinson's Disease by examining the expression of genes from normal blood and from... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20100298439 - Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors: Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing... Agent: Abelman, Frayne & Schwab

20100298442 - 1-amino-alkyl-cyclohexanes as 5-ht3 and neuronal nicotinic receptor antagonists: Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method... Agent: The Firm Of Hueschen And Sage

20100298440 - 1-aminocyclohexane derivatives for the treatment of hearing loss: The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.... Agent: The Firm Of Hueschen And Sage

20100298441 - Titration package for neramexane and its use in the treatment of an inner ear disorder: The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a... Agent: The Firm Of Hueschen And Sage

20100298443 - Methods and compositions for treating ophthalmic conditions with retinyl derivatives: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or... Agent: Wilson, Sonsini, Goodrich & Rosati

20100298444 - Method for improving the therapeutic efficacy of curcuminoids and their analogs: The invention relates to a method for increasing the therapeutic efficacy of curcuminoids and analogs. More specifically, the invention relates to a method for increasing the therapeutic efficacy of systemically administered formulations that contain curcuminoids and the equivalent therapeutics thereof. The method is characterized in that together with the administration... Agent: Innovar, LLC

20100298445 - Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses: The present invention is directed to a stable fluorocarbon emulsion having a continuous aqueous phase and discontinuous fluorocarbon phase comprising two fluorocarbons and surprisingly demonstrates that perfluorodecyl bromide is as effective in stabilizing perfluorooctyl bromide emulsions of certain concentrations than much more highly concentrated perfluorooctyl bromide/perfluorodecyl bromide emulsions without the... Agent: Kevin S Helmbacher

20100298446 - Actinically-crosslinkable siloxane-containing copolymers: The invention provide a class of actinically-crosslinkable silicone-containing prepolymers obtained by functionalizing an intermediary copolymer to have two or more thiol or ethylenically-unsaturated groups covalently attached thereto, wherein the intermediary copolymer is an atom-transfer radical polymerization (ATRP) product of a reactive mixture comprising a polysiloxane ATRP macroinitiator and at least... Agent: Ciba Vision Corporation Patent Department

20100298447 - Composite product of low-solubility drug and surfactant, and process for production thereof: This invention is intended to improve the solubility and permeability of low-solubility drugs, including drugs hardly soluble in water, classified as Class 2 or 4 in accordance with BCS by modifying such drugs into S/W, S/O, or S/O/W preparations. The S/W, S/O, or S/O/W preparations of low-solubility drugs of this... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20100298448 - Penetration enhancers for fungicidal agents: i

  
11/18/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100292130 - Biological active proteins having increased in vivo and/or in vitro stability: The present invention relates to biologically active proteins comprising at least two domains wherein a first domain of said at least two domains comprises an amino acid sequence having and/or mediating said biological activity and a second domain of said at least two domains comprises an amino acid sequence consisting... Agent: Foley And Lardner LLP Suite 500

20100292129 - Methods and compositions for enhancing proteasome activity: This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100292131 - Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof: The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level... Agent: Knobbe Martens Olson & Bear LLP

20100292132 - Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent: The present invention is directed to the use of the peptide compound Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100292134 - Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue... Agent: Cooper & Dunham, LLP

20100292133 - Truncated glp-1 derivaties and their therapeutical use: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100292135 - Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens: Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100292136 - Polymyxin derivatives and uses thereof: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100292137 - Antibiotics and methods for producing them: The invention relates to cyclic peptides and methods for producing and using them. Provided is amongst others a method for determining whether a compound comprises antibiotic activity, the method comprising providing a cyclic peptide to a bacterium wherein a 23S rRNA in a 5OS ribosomal subunit does not comprises a... Agent: Traskbritt, P.C.

20100292138 - Peptide derived from hepatitis c virus: Disclosed is a pharmaceutical composition for the treatment of an HCV-related disease in a patient having HLA-A24 or -A3 supertype, wherein the pharmaceutical composition comprises a peptide having an amino acid sequence represented by the formula: YLLPRRGPRL (SEQ ID NO:1) as an active ingredient. Also disclosed is a composition for... Agent: Birch Stewart Kolasch & Birch

20100292139 - Topical drug delivery using phosphatidylcholine: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.... Agent: Sullivan & Worcester LLP

20100292140 - Antisense modulation of fibroblast growth factor receptor 4 expression: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression... Agent: Mcdermott Will & Emery LLP

20100292141 - Insulin nasal powder inhalation: An inhalable nasal powder preparation of insulin and its preparing process are provided. The powder inhalation is consisting of self-emulsifying freeze-dried powder and pharmaceutically acceptable carriers. The dry powder comprises insulin, fat(s), emulsifier(s), antioxidant(s), supporting agent(s), bio-gel adhesive(s), and pH modifier(s), wherein the emulsifier is a mixture of lecithin and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100292142 - Novel neurotrophic factors: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.... Agent: Fish & Richardson

20100292143 - Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application: Pyrrole-2-carboxamide derivatives, their polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, beneficial for prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these pyrrole-2-carboxamides.... Agent: K&l Gates LLP

20100292144 - Sustained delivery of exenatide and other peptides: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.... Agent: Foley And Lardner LLP Suite 500

20100292145 - Methods of regulating apoptosis: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that... Agent: Knobbe Martens Olson & Bear LLP

20100292146 - Composite bone repair material: The present invention relates to a sliceable composite bone repair material comprising a porous block-shaped ceramic scaffold and a stabilizing polymer disposed therein. Said ceramic scaffold is a synthetic ceramic material or a naturally-derived material. Additionally said scaffold comprises interconnected macropores.... Agent: Rissman Hendricks & Oliverio, LLP

20100292147 - Identification of the hepcidin binding site on ferroportin: The invention relates to materials and procedures for the use of the hepcidin binding domain (HBD) on ferroportin. A 20 amino acid peptide of the HBD was synthesized and shown to recapitulate the characteristics and specificity of hepcidin binding to cell surface ferroportin. The affinity of hepcidin for the HBD... Agent: Morriss Obryant Compagni, P.C.

20100292148 - Targeted polylysine dendrimer therapeutic agent: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.... Agent: Knobbe Martens Olson & Bear LLP

20100292149 - Modulation of the neuroendocrine system as a therapy for motor neuron disease: The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method... Agent: Pabst Patent Group LLP

20100292150 - Treatment of menorrhagia with aromatase inhibitor: The present invention provides a method for treating menorrhagia in a premenopausal woman, which includes administering to the woman in need thereof a pharmaceutically effective amount of an aromatase inhibitor. Also within the scope of this invention is a pharmaceutical composition for the treatment.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100292151 - Use of human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.... Agent: Zymogenetics, Inc. Intellectual Property Department

20100292152 - Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases: Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100292153 - Use of muramyl dipeptide (mdp) for treating inflammation: The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).... Agent: Nih-ott C/o Sheridan Ross P.C.

20100292155 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific... Agent: Fulbright & Jaworski L.L.P.

20100292156 - Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof: Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.... Agent: Lucas & Mercanti, LLP

20100292154 - Protein profile for osteoarthritis: The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expression is correlated with OA and OA progression. Methods and kits are described for using these protein expression profiles in... Agent: Choate, Hall & Stewart LLP

20100292157 - Combination treatments for alzheimer's disease and similar diseases: The invention relates generally to novel compositions and methods comprising a cyclohexanehexol and a secretase inhibitor. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diseases involving a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100292158 - Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances: Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof... Agent: Mccarter & English, LLP Hartford Cityplace I

20100292159 - Method of treatment or prophylaxis of inflammatory pain: This invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals and particularly in human subjects. The AT2 receptor antagonists may be provided alone or in combination with... Agent: Perkins Coie LLP

20100292163 - Antitumoral compounds: i

20100292164 - Dimerized peptide: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100292160 - Hla-a* 3303-restricted wt1 peptide and pharmaceutical composition comprising the same: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100292161 - Polypeptides and methods of use: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the... Agent: Duane Morris LLP - BostonIPDepartment

20100292162 - Socs-3 promoter methylation in cancer: This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression.... Agent: Townsend And Townsend And Crew, LLP

20100292165 - Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation: The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to methods and pharmaceuticals for the treatment of intestinal neoplasia. The invention discloses the surprising finding that inhibitors of Notch pathway activation (for example, γ-secretase inhibitors) are extremely useful in the treatment of intestinal adenoma... Agent: Traskbritt, P.C.

20100292167 - C-met kinase binding proteins: Polypeptides comprising monomer domains that bind to c-MET, or portions thereof, are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100292166 - Pharmaceutical composition for treating malignant tumors containing human p31 genes: A pharmaceutical composition for the treatment of malignant tumors comprising a human p31comet gene encoding protein represented by SEQ ID NO: 3 or 4 as an effective component is provided. The pharmaceutical composition can suppress cancer cell growth, induce apoptosis and kill cells by overexpressing p31comet in the solid malignant... Agent: Cantor Colburn LLP

20100292168 - Protein mixture and use thereof in the preparation of a product that is intended for oral or enteral administration: This invention relates to a novel protein mixture and the use thereof in the preparation of a food product intended for oral or enteral nutrition. This protein mixture, based on caseinate, pea proteins and milk serum proteins has very high protein quality indices (protein efficiency index) and a good digestibility,... Agent: Quinn Emanuel Urquhart & Sullivan, LLP

20100292169 - Methods and compositions for regulating hdac6 activity: The present invention provides methods and compositions for inhibiting Hsp90 activity in a cell, comprising contacting the cell with an inhibitor of histone deacetylase 6 (HDAC6)... Agent: Myers Bigel Sibley & Sajovec

20100292171 - Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin: Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of... Agent: Suzannah K. Sundby (uc) Smith, Gambrell & Russell, LLP

20100292170 - Methods for diagnosing and treating pelvic pain disorders via beta-catenin: Methods for diagnosing a pelvic pain disorder that include analyzing samples for increased levels and/or nuclear accumulation of beta-catenin, which indicates presence of the pelvic pain disorder, particularly interstitial cystitis. Therapeutic treatment of a pelvic pain disorder, particularly interstitial cystitis, includes the administration to a patient of an effective amount... Agent: Nixon Peabody LLP - Patent Group

20100292172 - Peptide-peptidase inhibitor conjugates and methods of using same: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100292173 - Wound healing compounds and methods: The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide... Agent: Medlen And Carroll, LLP

20100292174 - Caspase inhibitors in the treatment of infection-associated preterm delivery: Apoptotic processes induced by infection of, or injury to, fetal and placental tissues have been implicated in preterm delivery. Thus, modulation of apoptotis constitutes a strategy for improving pregnancy outcome in women with intrauterine infections. Caspase inhibitors, including the pancaspase inhibitor Z-VAD-FMK, can be used to prevent apoptosis and, thus,... Agent: Davis Wright Tremaine LLP/los Angeles

20100292175 - Use of hydroxyflavan derivatives for taste modification: o

20100292176 - Antitumor agent:

20100292178 - Method of treating non-insulin dependent diabetes mellitus and related complications: A method of restoring insulin beta cells in a living object to lower a plasma sugar level comprising the step of providing a composition of berberine and catalpol as the two major active ingredients of said composition. The composition is preferably include oleanolic acid and taurine as active ingredients. The... Agent: David And Raymond Patent Firm

20100292177 - Methods of treatment using combination therapy: Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.... Agent: Jones Day

20100292179 - Target: We describe the functional cloning and the use of a non-fungal inositol phosphoryceraminde synthase (IPC synthase) in a screening assay for the identification of agents that target and antagonize the activity of IPC synthase.... Agent: Alston & Bird LLP

20100292180 - Pharmaceutical compositions comprising crystal forms of 5-azacytidine:

20100292300 - Compositions and methods for inhibiting or reversing fibrotic disorders: The present invention provides compositions and methods for inhibiting or reversing fibrotic disorders by administering a Hic-5 antagonist to a mammal in need thereof. The invention also includes methods for screening compounds to identify Hic-5 antagonists useful in inhibiting or reversing fibrotic disorders.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100292306 - Compositions and methods for the treatment of muscular dystrophy: Compositions and methods for treatment of individuals diagnosed with a dystrophin deficiency are disclosed. In particular, inhibitors of NFκB transactivation and/or inhibitors that suppress p65 expression are used to prevent and/or reverse muscle damage in animals or humans lacking dystrophin. Such compositions and methods are useful in the treatment of... Agent: Lathrop & Gage LLP

20100292304 - Compounds and methods for improving cellular uptake of oligomeric compounds: The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake.... Agent: Knobbe, Martens, Olson & Bear, LLP

20100292303 - Gene expression profile for predicting ovarian cancer patient survival: A gene profiling signature for predicting ovarian cancer patient survival is disclosed herein. The gene signature can be used to diagnosis or prognosis ovarian cancer, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments.... Agent: Klarquist Sparkman, LLP (ott-nih)

20100292302 - Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity: This invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for treating tumors by inhibiting the activity of CPT1C. The methods and compositions can additionally include inhibition of glycolysis.... Agent: Lando & Anastasi, LLP

20100292298 - Method and reagents for treating hepatic fibrosis and inflammation: The invention relates to methods for identifying an anti-fibrotic or anti-inflammatory agent comprising determining cathepsin S expression in activated hepatic stellate cells which have been exposed to a test compound and comparing expression to non-exposed hepatic stellate cells. The invention also relates to methods for treating a disorder characterised or... Agent: Klarquist Sparkman, LLP

20100292297 - Micrornas that regulate muscle cell proliferation and differentiation: The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100292301 - Novel sirna structures: The present invention provides novel compounds, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of a target gene. More specifically, the present invention relates to positional motifs of modified ribonucleotides useful in the design of siRNA compounds. In particular, the ribonucleotides include... Agent: Foley & Lardner LLP

20100292299 - Nucleotide motifs providing localization elements and methods of use: The instant invention describes nucleotide motifs comprising a localization element and small RNA molecules comprising the localization motifs, and methods of use in gene silencing. The nucleotide motifs have use in preventing and treating diseases or disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100292305 - Rnai modulation of hif-1 and theraputic uses thereof: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.... Agent: Alnylam/fenwick

20100292312 - Anti-dll4 antibodies and methods using same: The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20100292307 - Construct: A promoter for high level and sustained expression is provided which can be used for gene expression of chosen sequences in general. In particular, a nucleic acid construct comprising a hCEF1 promoter operably linked to a sequence for expression is provided, where the hCEF1 promoter comprises: (i) a human CMV... Agent: Fenwick & West LLP

20100292309 - Inducing immune-mediated tumor cell death: This document provides methods and materials related to treating cancer. For example, methods and materials that include using CD40L polypeptide, an hsp70 polypeptide, and a cytotoxic polypeptide to trigger an immune response directed against cancer cells are provided.... Agent: Fish & Richardson P.C.

20100292310 - Micro-rna scaffolds and non-naturally occurring micro-rnas: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence.... Agent: Merchant & Gould PC

20100292308 - Microrna molecules: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100292311 - Oligomeric compounds for the modulation of survivin expression: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin,... Agent: Dechert LLP

20100292181 - Compositions and methods for detecting and treating hiv infections: HIV infection can be detected by measuring phosphorylation levels of the actin-depolymerizing factor (AFD)/cofilin family, and infection can be treated and/or prevented by modulating the HIV co-receptor signaling pathway.... Agent: Foley And Lardner LLP Suite 500

20100292182 - Compositions and methods for detecting and treating hiv infections: Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.... Agent: Traskbritt, P.C.

20100292183 - Tetracycline and uses thereof: Provided herein are methods and compositions for the in vitro formation of tetracycline conjugates, for example, tetracycline conjugated to anti-coagulants. The present invention also provides methods for preventing or treating plaque-related diseases or disorders such as atherosclerosis using tetracycline alone, or the tetracycline conjugates of the present invention.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100292184 - 17beta-cyano-19-androst-4-ene derivative, its use and medicaments comprising the derivative: The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, in which R is hydrogen or C1-C4-alkyl, R1, R2 are each independently hydrogen or methyl, or R1... Agent: Millen, White, Zelano & Branigan, P.C.

20100292185 - Beta-lactamase inhibitors: Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100292186 - Pharmaceutical composition for treatment or prevention of liver cancer: An object of the present invention is to provide an excellent liver cancer treatment agent or prevention agent. The present invention provides a pharmaceutical composition for treating or preventing liver cancer, comprising menatetrenone, which is one species of vitamin K, and a phospholipid, said phospholipid being preferably egg yolk lecithin... Agent: Morgan Lewis & Bockius LLP

20100292187 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Hoffmann & Baron, LLP

20100292188 - Compounds comprising a cyclobutoxy group: The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100292189 - Oligonucleotide analog and method for treating flavivirus infections: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of... Agent: Seed Intellectual Property Law Group PLLC

20100292190 - Novel tubulin polymerisation inhibitors: The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds.... Agent: Woodcock Washburn LLP

20100292191 - Alkylene oxide adducts of oligosaccharides: The invention is related to alkylene oxide adducts of oligosaccharides, obtained by a process comprising alkoxylating at least one water-soluble oligosaccharide in aqueous solution at a temperature in the range of 90 to 160° C. The compounds are useful as adjuvants in agrochemical compositions.... Agent: Fox Rothschild LLP

20100292192 - Angiotensin ii receptor antagonists: e

20100292193 - Radioprotective drugs: Drugs and their compositions useful in preventing and treating negative side effects associated with radiation exposure or clinical radiotherapy are disclosed. More specifically, new compounds that can be administered systemically to patients exposed to radiation or undergoing radiotherapy and methods of using these formulations are disclosed.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100292194 - Formulas comprising highly soluble elements and vitamins for the prevention and amelioration of osteoporosis: The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100292195 - Low burst polymers and methods to produce polymer: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG... Agent: Schwegman, Lundberg & Woessner, P.A.

20100292196 - Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions... Agent: Ranbaxy Inc.

20100292197 - Compositions and methods for increasing telomerase activity: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing... Agent: Geron Corporation Attn. David J. Earp

20100292198 - Cyclic progestin regimens and kits: A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to... Agent: Howson & Howson LLP / Wyeth LLC

20100292199 - Transcutaneous pharmaceutical compositions containing a steroid hormone: The present invention concerns aqueous-alcoholic, single-phase transcutaneous pharmaceutical compositions with an amount of alcohol of greater than 30% containing a steroid hormone combined with at least one penetrating agent selected from propylene glycol fatty acid esters, terpene derivatives, and mixtures thereof.... Agent: Birch Stewart Kolasch & Birch

20100292200 - Methods for modulating apoptosis in platelets: The description discloses methods of enhancing or maintaining the viability or lifespan of platelets comprising administering an agent that down modulates apoptosis. The description also discloses a method of decreasing the survival, lifespan or viability of platelets comprising administering an effective amount of an agent that enhances apoptosis.... Agent: Clark & Elbing LLP

20100292201 - Novel steroidal esters of 17-oximino-5-androsten-3beta-ol: The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in... Agent: Abelman, Frayne & Schwab

20100292202 - Fungicidal compositions for turf treatment and improvement: The present invention relates to novel compositions comprising a fungicide that inhibits mitochondrial respiration at the QoI site, (QoI inhibitor), a contact fungicide, a demethylation inhibitor and pigments, which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the fungicidal compositions are able to control mold and fungus infection in... Agent: Bayer Cropscience Lp

20100292203 - Heterocyclic aspartyl protease inhibitors: e

20100292204 - Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists:

20100292206 - Heterocyclic compound:

20100292205 - Pyrimidone compounds as gsk-3 inhibitors: The invention pertains to pyrimidone compounds that serve as effective GSK-3 inhibitors. The invention further relates to pharmaceutical compositions and methods comprising such pyrimidone compounds; and the use of such compounds for treating certain disorders.... Agent: Pfizer Inc. Patent Department

20100292208 - Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase: Compounds with two fused bicyclic heteroaryl moieties and their pharmaceutical compositions, and methods of using them as leukotriene A4 hydrolase (LTA4H) modulators and for the treatment of diseases, disorders and conditions mediated by LTA4H.... Agent: Philip S. Johnson Johnson & Johnson

20100292207 - Substituted indazole derivatives active as kinase inhibitors: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like... Agent: Scully Scott Murphy & Presser, PC

20100292209 - Methods for identifying compounds that modulate neurotrophic factor signaling: The invention relates to screening for compounds and compositions that modulate neurotrophic factor signaling as reflected by modulation of factor-induced neurite outgrowth. The compounds and compositions are useful in the treatment of a variety of disorders. The invention also provides methods for preparing compounds for treatment of such disorders.... Agent: Wolf Greenfield & Sacks, P.C.

20100292210 - Novel compounds for a-beta-related pathologies: The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with γ-secretase and/or its... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100292211 - Antipsychotic treatment based on snp genotype: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.... Agent: Hoffman Warnick LLC

20100292212 - New azacyclic derivatives: e

20100292213 - Anti-inflammatory agents:

20100292214 - Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans: The Invention relates to compounds having an antiparasitic activity, and to their use as a drug, in particular as a drug for the prevention and/or treatment of parasitic diseases caused by apicomplexans. The invention also relates to pharmaceutical compositions containing those compounds.... Agent: Morgan Lewis & Bockius LLP

20100292215 - 11beta-hydroxysteroid dehydrogenase type 1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment... Agent: High Point Pharmaceuticals, LLC

20100292216 - Methods and compositions for the treatment of psychiatric conditions: This invention relates to methods and compositions for treating psychiatric conditions, such as depression.... Agent: Adamas Pharmaceuticals, Inc.

20100292217 - Ranolazine for the treatment of cns disorders: The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100292218 - Treatment of neurofibromatosis with radicicol and its derivatives: The present invention provides compounds of formulae Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va and the therapeutic use thereof. The present invention also includes methods of treating NF2-deficient or NF1-deficient cells or neurodegenerative diseases with radicicol or its derivatives, such as one or more compounds of formula I,... Agent: Cooley LLP Attn: Patent Group

20100292219 - Tertiary amine substituted peptides useful as inhibitors of hcv replication: The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R1-R12 in Formula I are described herein. The invention also includes methods for preparing such compounds. The present invention further includes pharmaceutical compositions containing tertiary amine substituted peptides and... Agent: Cantor Colburn LLP

20100292220 - Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor: e

20100292221 - Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor:

20100292222 - Chemical compounds 751:

20100292223 - Indazole-carboxamide compounds: The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20100292224 - Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators: wherein R1 represents optionally substituted C1-4 alkyl; X represents —(CR10R11)n— in which n represents 1 or 2; R2, R3 and R4 independently represent H, F or Me; and R5; R6; R7; R8 and R9 independently represent hydrogen, halogen, or cyano; or optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100292225 - Aryl pyridine as aldosterone synthase inhibitors: e

20100292226 - Active compound combinations having insecticidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, anthranilamides and, secondly, further insecticidally active compounds as defined in the description, which combinations are highly suitable for controlling animal pests, such as insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100292227 - Inhibitors of human immunodeficiency virus replication: e

20100292228 - Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists: This invention concerns substituted oxa-diaza-spiro-[5.5]-undecanone derivatives having neurokinin antagonistic activity, in particular an NK1 antagonistic activity, an NK3 antagonistic activity, a combined NK1/NK2 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of... Agent: Woodcock Washburn LLP

20100292229 - Tryphostin-analogs for the treatment of cell proliferative diseases: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc... Agent: Fulbright & Jaworski L.L.P.

20100292230 - Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders: The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100292233 - Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists: The present invention relates to certain (1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the... Agent: Fish & Richardson P.C.

20100292231 - Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers: e

20100292232 - Non-nucleoside reverse transcriptase inhibitors:

20100292234 - Triazole fused heteroaryl compounds and methods of use thereof: wherein A1, A2, A3, A4, A5, A6, R1 and R5 are defined herein. The invention further provides pharmaceutical compositions including one or more compounds of Formula I, use of such compounds and compositions for treatment of p38 MAP kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammatory disorders, as... Agent: Amgen Inc.

20100292235 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: e

20100292236 - 5-membered heterocyclic amides and related compounds: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100292237 - Method for combating phytopathogenic fungi: The present invention relates to the use of an active compound that inhibits the mitochondrial breathing chain at the level of the b/c1 complex for combating phytopathogenic fungi.... Agent: Brinks, Hofer, Gilson & Lione

20100292238 - Phenoxymethyl heterocyclic compounds: Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.... Agent: Fish & Richardson PC

20100292241 - 3,5-substituted-1,3-oxazolidin-2-one derivatives: The present invention is directed to 3,5-disubstituted-1,3-oxazolidin-2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neuro-ological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also... Agent: Merck

20100292239 - Novel microbiocides: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100292240 - Sulfonamide compounds: Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100292242 - Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof: Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20100292243 - 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20100292245 - (en) substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof: Ar represents optionally substituted aryl or optionally substituted heterocyclyl; R1 and R3 independently of each other represent C1-C3 alkyl or aryl; R2 represents hydrogen or C1-C3 alkyl; R41, and R42 independently of each other represent hydrogen, optionally substituted C1-C3 alkyl or optionally substituted phenyl, or R41, and R42 together with... Agent: Vera Chernobylsky

20100292244 - Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor: The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer.... Agent: Viksnins Harris & Padys Pllp

20100292246 - Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione: The instant invention provides formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione; processes for the production of such formulations; and methods of treating HIV or AIDS with such crystalline materials or such formulations.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100292247 - Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100292248 - Combination preparations comprising slv308 and a dopamine agonist: j

20100292249 - Manufacture of rimcazole: The present invention relates to a process for preparing Rimcazole and its salts.... Agent: Myers Bigel Sibley & Sajovec

20100292250 - Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20100292251 - Montelukast benzhydryl piperazine salts and process for preparation thereof: The invention relates to Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III). Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III) for the preparation of substantially pure [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid or its alkali salts and pharmaceutical composition... Agent: Merchant & Gould PC

20100292252 - Vinyl-aryl derivatives for inflammation and immune-related uses: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp. C/o Wolf, Greenfield & Sacks, P.C.

20100292253 - Pesticidal compositions: This document discloses molecules having the following formula (“Formula I”):... Agent: Dow Agrosciences LLC

20100292254 - Fused pyrimidine derivatives as trpv3 modulators: The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as... Agent: Kaplan Gilman & Pergament LLP

20100292255 - Therapeutic compounds and their use in treating diseases and disorders: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.... Agent: Myrexis, Inc. C/o Cpa Global

20100292256 - (en) 2-alkylamino-3-arylsulfonyl-cycloalcano [e or d] pyrazolo [1,5-a]pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof: wherein: R1 is hydrogen or C1-C3 alkyl; R2 is C1-C3 alkyl; R3 is hydrogen, one or more optionally identical halogen atoms, C1-C3 alkyl or hydroxyl group optionally substituted with C1-C3 alkyl; n is the whole numbers 1, 2 or 3.... Agent: Vera Chernobylsky

20100292257 - Uses of 2-[piperidinyl] methyl-2, 3-dihydroimidazo [1,2-c] quinazolin-5 (6h)-one for providing an analgesic effect, anti-allergic effect and histamine h1 receptor antagonism effect: The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H1 receptor antagonism effect in a patient to treat a disease or disorder, such as allergy.... Agent: Bacon & Thomas, PLLC

20100292259 - Pyrimidyl indoline compound: It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100292258 - Substituted aromatic heterocyclic compounds as fungicides: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in claim 1 or a salt or N-oxide thereof and their use in methods for the control and/or prevention of fungal infection, particularly in plants.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100292260 - 6-vinyl pyrimidine and pyrimidinone derivatives and the use thereof: The invention relates to 6-vinyl pyrimidine pyrimidinone derivatives and the use thereof as medicaments in particular for the treatment of HTV infections, the use thereof for preparing pharmaceutical compositions and methods for the preparation thereof.... Agent: Lucas & Mercanti, LLP

20100292261 - Quorum sensing antagonist, method of preventing a biofilm formation using the quorum sensing antagonist and method of reducing a bacterial contamination using the quorum sensing antagonist: In the quorum sensing antagonist blocking the communication in bacteria, the method for preventing biofilm formation using this quorum sensing antagonist and the method for reducing the bacterial contamination, the quorum sensing antagonist contains the homoserine lactone moiety and sulfanylethanoyl group, and has a similar chemical structure to that of... Agent: Lee, Hong, Degerman, Kang & Waimey

20100292262 - 4 (pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-amine derivatives: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100292263 - Cgrp receptor antagonists with tertiary amide, sulfonamide, carbamite and urea groups: (wherein variables A, m, n, J, Re, Rf, R4, Ea, Eb, Ec, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine; and pharmaceutical compositions comprising these... Agent: Merck

20100292265 - Pack of medicinal tablets: A water- and oxygen-occlusive pack is described. The pack encloses an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof.... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20100292264 - Small molecules with antiprotozoal activity: The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria.... Agent: Shuren Zhu

20100292266 - Oxazolyl piperidine modulators of fatty acid amide hydrolase: Certain oxazolyl piperidine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain,... Agent: Philip S. Johnson Johnson & Johnson

20100292267 - Palonosetron free base and process for its preparation: The present invention provides novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation. The present invention also provides a process for the preparation of palonosetron hydrochloride from the novel palonosetron free base in an amorphous form and/or in crystalline form-G.... Agent: Glenmark Generics Inc.

20100292268 - Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use: The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100292269 - Bir domain binding compounds: e

20100292271 - Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-ht6 receptor: The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R)... Agent: Abbott Gmbh C/o Polsinelli Shughart PC

20100292270 - Treatment of cachexia: The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100292272 - Supramolecular co-colloids produced using macrocyclic polyanionic systems: The present invention relates to a method preparing co-colloidal dispersions of active hydrophobic substances, such as pharmaceutical products, products having cosmetic properties or any other chemical product. The co-colloidal dispersions thus obtained are characterized in that they are formed by amphiphilic complexes resulting from combinations by non-covalent bonds between a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100292273 - Cannabinoid receptor modulators: Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from —C(R10)(R11)—*, —C(R10)(R11)—O—*, —C(R10)(R11)CH2—*, —C(R10)(R11)CH2—O—*, —CH2C(R10)(R11)—*, —CH2C(R10)(R11)—O—*. and —CH2—O—C(R10)(R11)—*, wherein the bond indicated by an asterisk is attached to the pyrazole... Agent: Banner & Witcoff, Ltd.

20100292275 - Fungicidal heterocyclic compounds: m

20100292274 - Haloalkyl heteroaryl benzamide compounds: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.... Agent: Foley And Lardner LLP Suite 500

20100292276 - Benzimidazole derivatives useful as trp m8 receptor modulators: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory... Agent: Philip S. Johnson Johnson & Johnson

20100292277 - Combination treatment of metabolic disorders: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a combination of a direct PPAR-gamma agonist and a Compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) Three of R1, R2, R3,... Agent: Wellstat Management Company. LLC

20100292278 - Methods of treating vascular disease and injury: The present invention provides a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a compound or composition that down-regulates or decreases the activity of microRNA-29 in the individual. Also provided is a method of down-regulating or decreasing... Agent: Benjamin Aaron Adler Adler & Associates

20100292279 - Bis-(sulfonylamino) derivatives in therapy: e

20100292280 - Anti-pyretic vasodilators: The invention provides vasodilating medication as means for lowering fever when administered to humans in need of such treatment. In particular, the use of B3 vitamin substances and Nitric Oxide-donor ingredients in compositions intended for use in reducing fever is introduced. The core composition substances can be used effectively on... Agent: Daniel Feigelson

20100292281 - Treatment of mci and alzheimer's disease: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof.... Agent: Choate, Hall & Stewart LLP

20100292283 - Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators: This invention relates to novel phenyl-acetamide and phenyl-propionamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100292282 - Synthesis and crystalline forms of cb-1 antagonist/inverse agonist: The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.... Agent: Merck

20100292285 - Methoxyacrylate-based fungicide and methods for preparing and using the same: The pharmaceutical composition of fungicide can further include an emulsifier, a cosolvent, a stabilizer, and a solvent. The fungicide can prevent and treat powdery mildew, downy mildew, gray mold, brown spot, scab of vegetables and fruits, southern leaf blight of corn, rice false smut, citrus stem-end rot, and rape sclerotinia... Agent: Matthias Scholl

20100292284 - Talarazole metabolites: Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO3H or O-gly; R1, ═H, OH, OSO3H, O-gly or =0; and gly=a glucuronate, or a pharmaceutically acceptable salt thereof. These compounds are targeted for the treatment of various skin-, hair- and nail-associated disorders.... Agent: Glaxo Smith Kline C/o The Nath Law Group

20100292286 - Crystalline imidazole-5-carboxylic acid derivative: The invention provides the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl) 1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy] methyl ester), its preparation method and uses thereof.... Agent: Myers Bigel Sibley & Sajovec

20100292287 - Periodontitis treatment: The periodontitis treatment is a method for the prevention and treatment of periodontitis in mammals, including humans and dogs. The mammal may be diabetic or non-diabetic. the method includes the step of administering an effective amount of an aldose reductase inhibitor (ARI). The ARI may be (i) a phenolic derivative,... Agent: Litman Law Offices, Ltd.

20100292288 - Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto: The present invention is directed to novel salts of (R)-1-{2-[4′-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and crystalline forms, and compositions thereof that modulate the activity of the histamine H3-receptor and are useful in the treatment of histamine H3-receptor associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such... Agent: Fish & Richardson P.C.

20100292289 - Treatment of metabolic syndrome with novel amides: The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention.... Agent: Ropes & Gray LLP

20100292290 - Novel process to prepare almotriptan: The present invention relates to a novel process for the preparation of almotriptan and pharmaceutically acceptable salts thereof, which affords product conveniently and efficiently with commercially acceptable yields and purity. The present invention also relates to a novel synthetic intermediate used in the process.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100292291 - Formulations of deacetylase inhibitors: The present invention provides a stable parenteral formulation of histone deacetylase inhibitors.... Agent: Novartis Corporate Intellectual Property

20100292292 - Treatment of neurodegenerative diseases using indatraline analogs: Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100292293 - Therapeutic substituted lactams: Disclosed herein are compounds having a formula: (I) Compositions, methods, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100292295 - 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators: wherein R1 represents C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkylmethyl-, phenyl-X— or heteroaryl, any of which may be optionally substituted; X represents —(CR12R13)n—; n represents 0 to 2; and R7, R8, R9, R10 and R11 independently represent H, halogen, or cyano; or optionally substituted C1-6 alkyl, C2-6... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100292294 - Compositions comprising a physiological coolant: It was found that substances represented by formula (I) are capable of bringing about greater cooling effects from reduced concentrations of physiological coolants without behaving as physiological coolants themselves, thereby enabling the preparation of compositions that do not necessarily have the characteristic minty odour of menthol-containing products and/or to allow... Agent: The Webb Law Firm, P.C.

20100292296 - Novel ligands that modulate rar receptors:

20100292313 - Compositions and methods for treating ischemia and ischemia-reperfusion injury:

20100292314 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100292315 - method for the treatment of food, feed and agricultural products with a polyene antifungal compound: The present invention provides an aqueous antifungal composition comprising a polyene antifungal compound and a thickening agent. The composition can be used in the protection against the development of fungi on food, feed and agricultural products.... Agent: Nixon & Vanderhye, PC

20100292316 - Improved therapeutic methods and compositions comprising chroman ring compounds: The instant invention concerns chroman ring derivative compounds such as vitamin E derivatives and methods for their use. In certain aspects, methods for treating subjects comprising Arg, JNK, p73, NOXA or FOXO1 positive cancers are provided. In still further aspects, methods for treating cell proliferative disease such as cancer by... Agent: Fulbright & Jaworski, L.L.P.

20100292317 - Antimicrobial and radioprotective compounds: The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single... Agent: Haynes And Boone, LLPIPSection

20100292318 - Antibacterial composition comprising salvia extracts: The present invention relates to a selectively purified tanshinone compounds containing extract from the root of a Salvia spp comprising Cryptotanshinone, Dihydrotanshinone, Tanshinone I, and Tanshinone IIA. It comprises at least 15%, by weight of the said identified tanshinone compounds and at least 4% by weight, of cryptotanshinone. The extract... Agent: Dickinson Wright PLLC

20100292320 - Benzofuran anilide histone deacetylase inhibitors: The present disclosure provides a compound of general Formula (I) having enzyme inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Gilead Sciences Inc

20100292319 - Process for preparing benzofurans: There is provided a process for the preparation of a compound of formula (I), wherein R1, R2, R3, R4, X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. Intermediate steps of the process comprise... Agent: Banner & Witcoff, Ltd.

20100292321 - Biofilm control: Compositions and methods suitable for killing bacteria and controlling biofilms comprising one or more microorganisms are provided wherein molecules capable of emulating cell-to-cell signal molecules of the microorganisms are utilized.... Agent: Albemarle Corporation Patent Department

20100292322 - Bis-platinum complexes with antitumor activity: A compound of general formula (I): in which: R is selected from the group consisting of (C1-C25)alkyl, (C2-C25)alkenyl, aryl, (C7-C10)aralkyl; n and m are each independently an integer of two to eight; p is one or two; A is selected from the group consisting of —B—, —B—(CH2)r—B—, —B—(CH2)r—B—(CH2)z—B—, wherein r... Agent: Seed Intellectual Property Law Group PLLC

20100292323 - Aqueous microemulsions containing pyrethroid compounds: The present invention relates to new aqueous microemulsions containing organic pesticide compounds of limited water-solubility and to their use for plant protection, including seed and crop protection, and protection or non-living material. The aqueous microemulsions comprise a) at least one pyrethroid compound P; b) at least one organic solvent, selected... Agent: Brinks, Hofer, Gilson & Lione

20100292324 - Multi-substituted diarylanilines as non-nucleoside hiv reverse transcriptase inhibitors, and preparation and use thereof: The present invention relates to multi-substituted m-diarylanilines or pharmaceutically acceptable salts thereof, wherein X, R1-R7 are as defined in the claims, their preparation process, pharmaceutical compositions comprising them and their use for the manufacture of a medicament for anti-HIV.... Agent: The Webb Law Firm, P.C.

20100292325 - P-menthawe-3-carboxylic acid esters to treat airways diseases: The present invention relates to methods and devices for treating sensory discomfort in the upper airways of a human; treating sensory discomfort in the oropharynx of a human; alleviating pain from pharyngitis in a human; alleviating cough in a human; and ameliorating the symptoms and signs of asthma, dyspnea, sleep... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100292326 - Pharmaceutical composition comprising s-nitrosoglutathione and polysaccharide: The invention relates to pharmaceutical compositions comprising S-nitrosoglutathione and one or more polysaccharide-type polimer(s) together with one or more pharmaceutically accepted polymer(s) and additive(s). The invention is based on the discovery that polysaccharide-type polymers (such as chitosan) are capable of stabilizing the otherwise highly labile GSNO.... Agent: Hahn & Voight PLLC

20100292327 - Treatment of aspirin resistance with betaine and/or betaine enriched molasses: Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of... Agent: Hovey Williams LLP

20100292328 - Cosmetic compositions containing esters of 2-ethylbutanol: The invention relates to the use of esters of 2-ethylbutanol with C4-36 carboxylic acids or C4-36 dicarboxylic acids in cosmetics and/or pharmaceutical preparations. The compounds are characterised by a particularly light feeling.... Agent: Fox Rothschild LLP

20100292329 - 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100292330 - Compositions and methods for enhancing cognitive function: The invention provides compositions comprising one or more long chain polyunsaturated fatty acids, nitric oxide releasing compounds, and medium chain triglycerides and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources, Inc.

20100292331 - Biomarkers for prostate cancer and methods using the same: Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer.... Agent: Brinks, Hofer, Gilson & Lione

20100292332 - Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine: The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly... Agent: Leydig Voit & Mayer, Ltd

20100292333 - Compositions suitable for the topical treatment of fungal infections of the skin and nails: The present invention relates to pharmaceutical compositions suitable for the topical treatment of fungal infections of the skin and nails, such as tinea pedia and tinea cruris, among others. The active ingredients of the present compositions are low molecular weight organic acids and their salts, many of which are previously... Agent: Heenan Blaikie LLP Bay Adelaide Centre

20100292334 - N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their to pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20100292335 - Use of organic compounds: The present invention provides methods for the prevention of, delay of progression to or the treatment of diseases modulated by an increase in tissue bradykinin levels by administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination... Agent: Dilworth & Barrese, LLP

20100292336 - Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same: Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Also disclosed are non-standard amino acid conjugates of amphetamine. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20100292337 - Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same: Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20100292338 - Silk medical device with antimicrobial properties and a method of manufacture thereof: A silk medical device is described, which is useful for the treatment of wounds to prevent infection. The silk medical device is manufactured from a silk protein material that is loaded with a polymeric cationic antimicrobial, such as polyhexamethylene biguanide (PHMB).... Agent: Intellectual Property / Technology Law

20100292339 - Genetic polymorphisms predictive of nutritional requirements for choline in subjects: Methods of predicting susceptibility of a subject to develop one or more choline deficiency-associated health effects are provided, comprising determining a genotype of the subject with respect to at least one choline metabolism gene and comparing the genotype of the subject with at least one reference genotype associated with susceptibility... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100292340 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100292341 - Quick dissolve compositions of memantine hydrochloride: The present invention relates to quick dissolve pharmaceutical compositions. More particularly the invention relates to quick dissolve pharmaceutical compositions of memantine hydrochloride capable of dissolving in the oral cavity and process for preparing such compositions. The quick dissolve pharmaceutical compositions of memantine hydrochloride contain at least one water-soluble diluent in... Agent: Seed Intellectual Property Law Group PLLC

20100292342 - Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver... Agent: David R Preston & Associates Apc

20100292343 - Use of a dialkylketone peroxide as biocidal, sterilizing, antiseptic, disinfecting and anti-parasitic agent: The invention presented here establishes the use of a dialkyl ketone peroxide as a sterilizing, antiseptic, disinfecting and anti-parasitic agent, with no apparent toxicity nor ecotoxicity, and a very wide spectrum of activity in terms of the type of organisms on which it acts (bacteria, virus, fungi, spores, mycobacteria, protozoa,... Agent: Ostrolenk Faber Gerb & Soffen

20100292344 - Methods and compositions for treating thalamocortical dysrhythmia: This invention relates to methods of inhibiting a Cav3 calcium channel in a cell using a C2-C10 alkyl alcohol, or mixtures thereof. This invention further relates to methods of treating a thalamocortical dysrhythmia disorder in a mammal and for treating a neurological disorder in a mammal associated with the thalamocortical... Agent: Wilmerhale/boston

20100292345 - Therapeutic uses of cannabigerol: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group:... Agent: Wolf Greenfield & Sacks, P.C.

20100292346 - Stereoisomers propofol therapeutic compounds: A (−)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100292347 - Process to thicken aqueous compositions, notably with an acid ph, by means of organophosphate polymers, and the aqueous compositions obtained: (

20100292348 - Detection of methylated dna and dna mutations: The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence.... Agent: Davis Wright Tremaine LLP/los Angeles

  
11/11/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100286020 - milk protein composition and use thereof: A milk protein composition for use in treating or preventing chronic local inflammation in humans is disclosed. The invention also relates to the use of the milk protein composition for the manufacture of a nutritional composition and/or pharmaceutical composition for use in treating or preventing chronic local inflammation in humans.... Agent: Choate, Hall & Stewart LLP

20100286023 - Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly: Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index.... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20100286022 - Edible and biocompatible metal-organic frameworks: The disclosure relates generally to materials that comprise organic frameworks. The disclosure also relates to materials that are useful to store and separate biological agents that are environmentally friendly and biocompatible.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100286021 - Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders: The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of anxiety-related disorders can be achieved by decreasing levels of PK2 and administering an effective amount of PK2 receptor antagonist. A method of modulating the behavioral response of a subject displaying symptoms of stress... Agent: Dla Piper LLP (us)

20100286024 - Insulinotropic compounds and uses thereof: The invention provides novel GLP-1 analogues and compositions comprising such analogues. The compounds of the invention are useful in treating diabetes mellitus and related disorders.... Agent: Steptoe & Johnson LLP

20100286025 - Synthetic apolipoprotein e mimicking polypeptides and methods of use: The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein... Agent: Ballard Spahr LLP

20100286026 - Novel protein: Provided is a novel, isolated polypeptide including an amino acid sequence of SEQ. ID. NO: 2 or SEQ. ID. NO: 4, and the nucleic acid molecule which encodes it. The polypeptide may be used in a method for treating various diseases including cancer, immune associated, viral and inflammatory diseases.... Agent: The Nath Law Group

20100286027 - Anti-bacterial compositions: The invention relates to an isolated protein for use as an antimicrobial agent comprises a plurality of LRR (leucine rich repeat) domains, each LRR domain independently comprising an amino acid sequence of formula (I): (F1LxxLxL(xxZ)YF2) wherein: F1 and F2 are independently, a contiguous amino acid sequence of between 1 and... Agent: Novartis Institutes For Biomedical Research, Inc.

20100286028 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100286029 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100286030 - novel bacteriocin from a new streptomyces species: Provided is an isolated novel Gram-positive non-motile, non-spore-forming, aerobic bacterium designated Streptomyces scopuloiridis, wherein the bacterium produces a bacteriocin that kills or inhibits the growth of Gram-positive or Gram-negative target bacteria. Also provided are novel purified polypeptides, and fragments thereof, and isolated nucleic acids from the bacterium. Further provided are... Agent: Mckeon Meunier Carlin & Curfman LLC

20100286031 - Antibiotic formulations, unit doses, kits and methods: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the... Agent: Novartis Corporate Intellectual Property

20100286032 - Prodrugs of hiv protease inhibitors:

20100286033 - New cyclic peptide compounds: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286034 - Uses for aqueous streams containing proteins: The present invention relates to a protein hydrolysate comprising free amino acids and peptides whereby the weight ratio of free amino acids to peptides is about 1:1 and wherein at least about 50 molar % of the peptides has a molecular weight of 400 Da or less. This composition may... Agent: Nixon & Vanderhye, PC

20100286035 - Neuromedin u derivative: The objective of the present invention is to provide a new antifeedant. The other objective of the present invention is to provide a NMU derivative showing a high antifeedant activity even in common administration forms such as peripheral administration. A neuromedin U derivative wherein a methoxypolyethylene glycol is bound via... Agent: Edwards Angell Palmer & Dodge LLP

20100286036 - Novel peptides that enhance tight junction permeability: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in... Agent: Cooley LLP Attn: Patent Group

20100286037 - Pharmaceutical and/or cosmetic composition containing active-principle activators of aconitase: The present invention relates to a cosmetic or pharmaceutical, and in particular dermatological, composition comprising, in a physiologically suitable medium, active ingredients capable of activating aconitase. These active ingredients may be polypeptides or peptides, used alone or in combination with at least one other active ingredient. The invention also relates... Agent: Young & Thompson

20100286038 - Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same: This application discloses a novel formulation containing a 3-amino-4-substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation.... Agent: Merck Patent Department (k-6-1, 1990)

20100286040 - Pro-angiogenic peptides and uses thereof: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.... Agent: Fennemore Craig

20100286039 - Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders: The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function... Agent: Marshall, Gerstein & Borun LLP

20100286041 - (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one: Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100286042 - Medicinal composition containing highly functionalized chimeric protein: There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a... Agent: Hogan Lovells US LLP

20100286043 - Use of neuregulin-1 in reducing brain damage: Methods of reducing and/or protecting against disorders in perinatal subjects are disclosed. Such methods can be used for disorders associated with neuronal cell damage. In certain aspects, the method comprises administering a therapeutically effective amount of neuregulin or a biologically active analog with a pharmaceutical carrier to a perinatal subject.... Agent: Nutter Mcclennen & Fish LLP

20100286044 - Detection of tissue origin of cancer: Disclosed is a method for determining the cellular or tissue origin of tumor cells. The method entails determining the presence of at least one micro RNA (miRNA) in a sample derived from tumor tissue and based on the said determination establishing a miRNA expression profile and comparing this with pre-established... Agent: Clark & Elbing LLP

20100286045 - Methods comprising desmopressin: The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286046 - Modified h2 relaxin for tumor suppression: Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor,... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100286047 - Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders: The present invention relates to the use of von Willebrand Factor (VWF) preparations or of a VWF preparation in combination with coagulation Factor VIII (FVIII) for extravascular administration in the therapy and prophylactic treatment of bleeding disorders.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286048 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286049 - Polycystic kidney disease-related gene and use thereof: A major gene of a pc mutant of a Japanese Medaka fish (Oryzias latipes) has been identified. Based on this finding, use of the gene is provided. A gene responsible for polycystic kidney in a Japanese Medaka fish is identified in the chromosomal region of the fish by performing a... Agent: Oliff & Berridge, PLC

20100286050 - Method of preventing progression of hypertension-induced heart failure with pkc peptides: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β1PKC, or βIIPKC peptide inhibitor, examples of which are provided.... Agent: King & Spalding LLP

20100286051 - Memory and learning impairments associated with disruption of ephrin receptor a6 (epha6) gene: The present application is directed to a method of treating or preventing or ameliorating a neurological disorder associated with the disruption of a gene which encodes for an EphA6 polypeptide, the method comprising administering to a subject in need of such treatment whom may already have the disorder, or may... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.

20100286052 - Novel use of antisecretory factor: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic... Agent: Buchanan, Ingersoll & Rooney PC

20100286053 - Plasminogen activator inhibitor amelioration of newborn hypoxic ischemic brain injury: Plasminogen activators as potential therapeutic targets in neonatal hypoxia ischemia (HI) brain injury. Use of plasminogen activator inhibitor-1 (PAI-1) to ameliorate HI encephalopathy related disease. Use of PAI-1 as preventive treatment of cerebral palsy (CP).... Agent: Thompson Hine L.L.P. Intellectual Property Group

20100286054 - Composition: The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44, MBP 83-99, MBP 131-145, and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.... Agent: Marshall, Gerstein & Borun LLP

20100286055 - Use of wnt3a for acceleration of wound healing: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a... Agent: Foley And Lardner LLP Suite 500

20100286056 - Compositions for reducing oxidative stress and uses thereof: The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrC and NpGLu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma,... Agent: Kagan Binder, PLLC

20100286057 - Methods and compositions for modulating bcl-2 family polypeptides: The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide.... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100286058 - Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation: Hypermethylation of the SPARC promoter is identified as a mechanism for repressing SPARC gene in cancer resulting in resistance to therapy. The restoration of SPARC expression with demethylating agents, such as 5-Aza-2′deoxycytidine, is shown to enhance chemosensitivity. The invention provides a mechanism of limiting the number of patients exposed to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100286060 - Specific binding agents of human angiopoeitin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Amgen Inc.

20100286059 - Use of opioid antagonists: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.... Agent: Michael Best & Friedrich LLP

20100286062 - Pharmaceutical compound: b

20100286061 - Plasmin-inhibitory therapies: The disclosure features a method of treating cancers, angiogenesis-related disorders and lymphangiogenesis-related disorders with plasmin inhibitors. An exemplary method includes: administering, to a subject, a plasmin inhibitor, such as a protein that includes a Kunitz domain that inhibits plasmin.... Agent: Lando & Anastasi, LLP

20100286063 - Gnrh agonist combination drugs: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from... Agent: Foley And Lardner LLP Suite 500

20100286064 - Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof: The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also... Agent: The Nath Law Group

20100286065 - Topical methods and compositions for the treatment of eye diseases and conditions: The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides... Agent: Young & Thompson

20100286066 - Alpha 1-antitrypsin compositions and treatment methods using such compositions: Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20100286067 - Glycoconjugation of polypeptides using oligosaccharyltransferases: The current invention provides polypeptides and polypeptide conjugates that include an exogenous N-linked glycosylation sequence. The N-linked glycosylation sequence is preferably a substrate for an oligosaccharyltransferase (e.g., bacterial PgIB), which can catalyze the transfer of a glycosyl moiety from a lipid-bound glycosyl donor molecule (e.g., a lipid-pyrophosphate-linked glycosyl moiety) to... Agent: Leydig Voit & Mayer, Ltd

20100286068 - Molecular markers of plant embryogenesis: The present invention relates generally to a molecular marker for a plant physiological process and more particularly for plant embryogenesis. The molecular marker is, in one form, a genetic sequence from a monocot plant such as but not limited to oil-palm plants. In another form, the molecular marker is a... Agent: Scully Scott Murphy & Presser, PC

20100286070 - Affinity tag: The present invention relates to an affinity tag especially useful for human applications. The invention further includes methods for preparing fusion molecules, as well as compositions and reaction mixtures which contain said fusion molecules, nucleic acid molecules which encode these fusion molecules and recombinant host cells which contain these nucleic... Agent: Nixon & Vanderhye, PC

20100286069 - Cationic peptide for delivering an agent into a cell: There is presently provided a triblock peptide comprising a hydrophobic amino acid block, a histidine block and a cationic amino acid block. The triblock peptide may be used to form a nanoparticle for delivery of an agent into a cell.... Agent: Klarquist Sparkman, LLP

20100286071 - Finger-1 peptide analogs of the tgf-beta superfamily: Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.... Agent: Wyeth LLC Patent Law Group

20100286072 - Retro-inverso peptides derived from interleukin-6: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the... Agent: Kenyon & Kenyon LLP

20100286073 - Compounds and methods for pharmaceutical use: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate... Agent: Wilmerhale/boston

20100286074 - Pharmaceutical use of ginsenoside or mixture thereof and pharmaceutical composition of ginsenoside and use thereof: The present invention provides a use of ginsenosides represented by formula I or mixtures thereof for manufacturing a medicament for anti-platelet aggregation, wherein R1 and R2 are H or glucosyl, and when R1 is glucosyl, R2 is H; when R1 is H, R2 is glucosyl. The present invention further provides... Agent: Chalker Flores, LLP

20100286075 - Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same: A taxane-containing amphiphilic block copolymer micelle composition, including taxane, an amphiphilic block copolymer containing a hydrophilic block and a hydrophobic block, and an osmolality adjusting agent, is described. Also described are a method for preparing the same composition. The composition has excellent stability so that it can prevent rapid release... Agent: Merchant & Gould PC

20100286076 - Ectoparasiticidal methods and formulations: Provided are novel methods and formulations for systemically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof.... Agent: Eli Lilly & Company

20100286077 - Compounds: The present invention provides a compound of formula (I′) which is a nystatin derivative having an additional double bond present between C28 and C29 and which is further modified relative to nystatin at one or more of positions C5, C7, C9, C10, C11, C16 or at the amino group of... Agent: Nixon & Vanderhye, PC

20100286078 - Topical ophthalmic compositions containing tobramycin and dexamethasone: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so... Agent: Alcon

20100286080 - Aqueous composition comprising chitosan and an acidic drug: The present invention relates to a composition comprising an aqueous solvent and a conjugate of at least one hydrophilic polymer having a primary amine functional group, a derivative or monomer thereof and at least one acidic drug; a method for its preparation and use thereof.... Agent: Patent Central LLC Stephan A. Pendorf

20100286079 - Composition comprising covalent conjugates of chitosan and an acidic drug and parenteral administration: The present invention relates to a composition comprising an aqueous solvent and a conjugate of at least one hydrophilic polymer having a primary amine functional group, a derivative or monomer thereof and at least one acidic drug; a method for its preparation and use thereof.... Agent: Patent Central LLC Stephan A. Pendorf

20100286081 - 5-amino-3-(2',3'-di-o-acetyl-beta-d-ribofuranosyl)-3h-thiazolo[4,5-d] pyrimidin-2-oce salts and crystalline forms: The invention relates to a maleate salt of 5-amino-3-(2′-3′-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing these crystalline forms.... Agent: Connolly Bove Lodge & Hutz LLP

20100286239 - Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation: The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present... Agent: David S. Resnick

20100286241 - Compositions comprising k-ras sirna and methods of use: The present invention provides nucleic acid molecules that inhibit K-ras expression. Methods of using the nucleic acid molecules are also provided.... Agent: Seed Intellectual Property Law Group PLLC

20100286236 - Dosage of oligonucleotides suitable for the treatment of tumors: A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m2/treatment cycle, the antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridizes with mRNA of TGF-beta-2, -1 and/or -3 for the preparation... Agent: Jacobson Holman PLLC

20100286245 - Identification of novel genes coding for small temporal rnas: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21 -nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100286246 - Identification of novel genes coding for small temporal rnas: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21 -nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100286231 - Method for identifying a renal fibrosis process use of snail- activity-inhibiting compounds in the production of pharmaceutical compositions, method for identifying said inhibiting compounds, said pharmaceutical compositions and applications thereof: The present invention relates to Snail, which is a protein that is directly involved in the etiopathogeny of renal fibrosis, in addition to being a marker of this disease. Therefore, the identification thereof may be used as a diagnosis for renal fibrosis. On the other hand, the Snail protein may... Agent: Darby & Darby P.C.

20100286228 - Method of inhibiting intimal hyperplasia: The present invention relates, in general, to intimal hyperplasia, and, in particular, to a method of inhibiting intimal hyperplasia using siRNA to E2F. The invention further relates to compounds and compositions suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20100286235 - Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals: The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′ diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for... Agent: Nixon Peabody, LLP

20100286232 - Microrna expression profile associated with pancreatic cancer: Methods are provided for diagnosing whether a subject has, or is at risk of developing, pancreatic cancer. The methods include measuring the level of at least one miR gene product in a biological sample derived from the subject's pancreas. An alteration in the level of the miR gene product in... Agent: Calfee Halter & Griswold, LLP

20100286240 - Micrornas for inhibiting viral replication: The present invention relates to reducing accumulation of viral genomes in a target cell. In particular the present invention provides compositions and methods for combating viral infection through RNA interference. Specifically the present invention provides cellular microRNA mimics for treating virus-infected subjects.... Agent: Morrison & Foerster LLP

20100286243 - Mig-7 as a specific anticancer target: Aspects of the present invention provide novel Mig-7 encoding nucleic acids and Mig-7 polypeptides, RNAi (such as siRNA), recombinant DNA expression systems and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis... Agent: Seed Intellectual Property Law Group PLLC

20100286229 - Modulation of androgen receptor for treatment of prostate cancer: The present invention provides methods for the reduction of endotoxins in a plasmid preparation using a carbohydrate non-ionic detergent with silica chromatography.... Agent: Polsinelli Shughart PC

20100286230 - Modulation of trpv expression levels: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea... Agent: King & Spalding

20100286233 - Peripheral and neural inflammatory crosstalk: Disclosed are compositions and methods for the study and treatment of inflammatory disease, neurological disorders, bone disease, pain, and methods of making and using thereof.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100286234 - Pharmaceutical composition comprising anti-mirna antisense oligonucleotides: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100286237 - Pro-angiogenic genes in ovarian tumor endothelial cell isolates: A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments.... Agent: Klarquist Sparkman, LLP (ott-nih)

20100286244 - Rnai mediated knockdown of numa for cancer therapy: This invention relates to the use of short interfering nucleic acid molecules (siRNA) to inhibit Nuclear Mitotic Apparatus Protein (NuMA) gene expression and their use in treatment of disease, including cancer.... Agent: Foley And Lardner LLP Suite 500

20100286242 - Sirna-mediated gene silencing of synuclein: The present invention is directed to small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs.... Agent: Brinks Hofer Gilson & Lione

20100286238 - Suppression of viruses involved in respiratory infection or disease: The present invention concerns methods and reagents useful in decreasing the level of or severity of respiratory infection or disease due to paramyxoviruses, such as RSV or HPIV, or coronavirus infection. Particularly, the invention relates to modulating gene expression using a multitargeting interfering RNA molecules that target multiple target sites... Agent: Philip S. Johnson Johnson & Johnson

20100286250 - Fluorinated lipids and methods of use: The invention provides methods and compounds for delivering agents to cells. The compounds can include a fluorinated lipid, a linker, and an agent for delivery to a cell.... Agent: Choate, Hall & Stewart LLP

20100286248 - Human fg01 gene and its applications: A human gene, fg01, on chromosome 8, is identified. This gene, and its expression product, human fg01, shares a homology under 70% with the corresponding murine gene, which has been linked to presentation of the Alzheimer's phenotype of Aβ plaques and hyperphosphorylated tau tangles. Upregulation appears to suppress the Alzheimer's... Agent: Steven B. Kelber Berenato & White, LLC

20100286252 - Human fg01 gene and its applications: A human gene, fg01, on chromosome 8, is identified, as well as a truncated form on chromosome 5. Upregulation appears to suppress the Alzheimer's phenotype, (AB plaques and hyperphosphorylated tau tangles) which may address the onset of symptoms or progression of symptoms associated with AD. Screening methods are also set... Agent: Steven B. Kelber Berenato & White, LLC

20100286251 - Mammalian genes involved in viral infection and tumor suppression: The present invention provides methods of identifying cellular genes used for viral, bacterial or parasitic growth. Also provided by the present invention are nucleic acids related to and methods of reducing or preventing viral, bacterial or parasitic infection.... Agent: Ballard Spahr LLP

20100286253 - Method for treating ocular neovascularization: Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.... Agent: Mdip LLC

20100286247 - Methods of protection from oxidative stress: Alterations in the structure of telomeres lead to modulation in the redox state of the cell. Substances which mimic destabilized telomeres, such as t-oligos, have a protective effect on future exposure of a cell to oxidative stress.... Agent: Howrey LLP - East

20100286249 - Micro-rnas modulating immunity and inflammation: MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100286082 - Riboswitches and methods and compositions for use of and with riboswitches: Riboswitches are targets for antibiotics and other small molecule therapies. Riboswitches and portions thereof can be used to regulate the expression or function of RNA molecules and other elements and molecules. Riboswitches and portions thereof can be used in a variety of other methods to, for example, identify or detect... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100286083 - Nucleoside analogs: A purified compound having activity against hepatitis C virus is disclosed.... Agent: Merchant & Gould PC

20100286084 - Oligomer-nucleoside phosphate conjugates: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20100286086 - Composition for the treatment of osteoarthritis: The present invention relates to compositions comprising chondroitin sulphate and mannosamine or a derivative thereof. The mannosamine derivative is preferably N-acetylmannosamine. The compositions may comprise glucosamine. Said compositions are useful in the treatment or prevention of degenerative joint diseases, preferably of osteoarthritis, in the treatment or prevention of tendon or... Agent: Sughrue Mion, PLLC

20100286085 - Novel chondroitin sulfate having decreased molecular weight and use thereof: e

20100286087 - Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases: One embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative and at least one other compound (B). Another embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative, which is to be used in combination with at... Agent: Fish & Richardson P.C.

20100286088 - 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in... Agent: Swanson & Bratschun, L.L.C.

20100286089 - Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation: Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100286092 - Beta-lactamase inhibitors: Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100286091 - Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.... Agent: Cantor Colburn LLP - National Institutes Of Health

20100286090 - Treatment of multiple myeloma: Methods for treating multiple myeloma comprising administering a therapeutically effective amount of dasatinib to a patient in need of treatment thereof. Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib. The patient may be refractory to prior treatment with an anti-neoplastic... Agent: Louis J. Wille Bristol-myers Squibb Company

20100286093 - Anti-inflammatory composition containing docosahexaenoyl lysophosphatidylamine as an active ingredient: The present invention relates to an anti-inflammatory composition containing docosahexaenoyl lysophosphatidylamine as an active ingredient. Particularly, one of polyunsaturated lysophosphatidylcholines, docosahexaenoyl lysophosphatidylcholine inhibits intracellular NO generation mediated by lipopolysaccharide and suppresses zymosan A induced peritonitis in vivo, suggesting that it has excellent anti-inflammatory effect but has no cytotoxicity, so that... Agent: Klarquist Sparkman, LLP

20100286094 - Novel compounds of reverse turn mimetics and the use thereof: Conformationally constrained compounds that are novel and mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins and having bicyclic framework are disclosed, as well as their prodrugs. Such reverse-turn mimetic structures and pro-drugs have utility over a wide range of fields, including use as diagnostic and... Agent: Seed Intellectual Property Law Group PLLC

20100286095 - Novel use of a polyamine-depleted food composition for human or veterinary use, for preparing a therapeutic food product: A polyamine-depleted food compositions is provided for preparing foods, intended for humans or animals, for preventing or treating heart rate anomalies.... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20100286096 - Methods of and formulations for reducing and inhibiting the growth of the concentration of microbes in water-based fluids and systems used with them: The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use an oxazolidine compound and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C1-C3 alkyl- and alkenyltris(hydroxymethyl)phosphonium... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100286097 - Insecticidal compositions: This invention relates to topical compositions for treating ectoparasites such as head lice and fleas. The composition comprises an ovicidally effective quantity of salicylic acid (typically 1-10% by weight) dispersed in a liquid vehicle or carrier. The vehicle may be an oily carrier including a mineral oil such as paraffin... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20100286098 - Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease: The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the... Agent: Wolf Greenfield & Sacks, P.C.

20100286099 - Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine: A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of... Agent: Notaro, Michalos & Zaccaria P.C.

20100286100 - Method and composition to improve absorption of therapeutic agents: A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon... Agent: Richard S. Bullitt Bayer Healthcare LLC

20100286101 - Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability: A composition that includes a corticosteroid (e.g., betamethasone dipropionate), a vitamin D analog (e.g., calcipotriene) and an acyl ester of 1,2,3-trihydroxypropane or an ether thereof; and a method of treating a dermatologic condition (e.g., psoriasis vulgaris) in a mammal (e.g., human); are provided. The method includes topically administering to a... Agent: Schwegman, Lundberg & Woessner, P.A.

20100286102 - Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage: the proportion by weight of (alpha-)bisabolol in the formulation being equal to or greater than the total proportion by weight of ceramides and/or pseudoceramides, and the total amount of components (a) and (b) being sufficient to strengthen the barrier of damaged and/or undamaged skin.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100286103 - Heterocycle-aryl compounds for inflammation and immune-related uses: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp. C/o Wolf, Greenfield & Sacks, P.C.

20100286104 - Agent for inhibiting visceral fat accumulation: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent... Agent: Knobbe Martens Olson & Bear LLP

20100286106 - Methods and apparatus for treating the prostate: Treating and/or preventing prostate problems and/or metastases, by selectively occluding various groin vessels and tools for selective occluding of various groin veins, including, for example, the deferential vein. Optionally providing anti-androgen treatment after such occluding.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100286105 - Methods of treating hyperandrogenism and conditions associated therewith by administering a fatty acid ester of an estrogen or an estrogen derivative: Compositions and methods for treating hyperandrogenism and conditions associated therewith, including polycystic ovary syndrome are disclosed. The invention is directed to methods for treating hyperandrogenism and conditions associated therewith, in a subject comprising administering a fatty acid ester of an estrogen or an estrogen derivative. Furthermore the invention is directed... Agent: Hoxie & Associates LLC

20100286107 - Oligomer-corticosteroid conjugates: The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not... Agent: Nektar Therapeutics

20100286108 - Stabilized steroid composition and method for its preparation: Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing... Agent: Pharmaceutical Patent Attorneys, LLC

20100286109 - Amide derivatives as positive allosteric modulators and methods of use thereof: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20100286113 - Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors: The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100286111 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Fish & Richardson P.C.

20100286112 - Compounds for the treatment of metabolic disorders: The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100286114 - Hedgehog pathway antagonists and therapeutic applications thereof: Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications.... Agent: Lucas & Mercanti, LLP

20100286115 - Pyrazoles: The present invention is concerned with isoxazole-pyrazoles of formula I, having affinity and selectivity for GABA A a5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutics. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100286117 - Pyridines: wherein X, R1, R2, R3 and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100286116 - Thiazoles: The present invention is concerned with isoxazole-thiazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100286118 - Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750: e

20100286110 - Azetidinyl g-protein coupled receptor agonists: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.... Agent: Osi Pharmaceuticals, Inc.

20100286119 - N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof: m

20100286120 - Pyridooxazepine derivative and use thereof:

20100286121 - Water-immiscible materials as vehicles for drug delivery: A pharmaceutical composition includes at least one pharmaceutical component and at least one water-immiscible material. The pharmaceutical component is more soluble in the water-immiscible material than in water. The pharmaceutical composition is suitable for ocular administration.... Agent: Bausch & Lomb Incorporated

20100286122 - Cgrp antagonist salt: An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1′-carbonyldiimidazole (“CDI”) as carbonyl source; an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide; efficient syntheses for the preparation of intermediates (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride, and the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide including the potassium salt... Agent: Merck

20100286123 - Inhibitors of the renal outer medullary potassium channel: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such... Agent: Merck

20100286124 - Prop-2-yn-1-amine inhibitors of monoamine oxidase type b: The present invention relates to new prop-2-yn-1-amine inhibitors of monoamine oxidase type B activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100286125 - Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning: e

20100286126 - Organic compounds:

20100286127 - Antitumor agent:

20100286128 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine-receptor ligands: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20100286129 - Novel benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same: The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.... Agent: Millen, White, Zelano & Branigan, P.C.

20100286130 - Antimicrobial compounds, their synthesis and their use for treatment of mammalian infections: or salts thereof wherein R′, R2, R3, R4, R5, R6, and other variables enumerated under one or more of same are as defined herein. Compounds of Formula I have activity as antimicrobial agents. Also disclosed are pharmaceutical compositions and methods of treating and preventing microbial infections in mammals, for example,... Agent: Jordan And Hamburg LLP

20100286132 - Pyridines: The present invention is concerned with isoxazole-pyridines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as pharmaceuticals. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100286131 - Viral polymerase inhibitors: e

20100286133 - Diacyl indazole derivatives as lipase and phospholipase inhibitors:

20100286134 - Novel phenoxazin-3-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20100286136 - Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders: The invention provides methods of using dihydronaphthyridinyl and related compounds to treat opthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.... Agent: Goodwin Procter LLP Patent Administrator

20100286135 - Heterocyclic amide compounds as protein kinase inhibitors: The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation,... Agent: Merck Patent Department (k-6-1, 1990)

20100286137 - Method of treating conditions involving ppar-receptors with indole compounds: e

20100286138 - Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide: Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100286139 - Amino pyrazole compound: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.... Agent: Eli Lilly & Company

20100286140 - Triazolophthalazines: e

20100286141 - Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.... Agent: Dann, Dorfman, Herrell & Skillman

20100286142 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf-1 protein kinase, and may also... Agent: Foley & Lardner LLP

20100286143 - Methods and materials for genetic analysis of tumors: This invention relates generally to methods and materials for rapid detection of mutations for tumor genotyping.... Agent: Fish & Richardson PC

20100286144 - Heteroaryl derivatives: wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene,... Agent: Birch Stewart Kolasch & Birch

20100286146 - Carboxamide compounds and their use as calpain inhibitors: in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or... Agent: Abbott Gmbh C/o Polsinelli Shughart PC

20100286145 - Isophthalamide derivatives inhibiting beta-secretase activity: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.... Agent: Morrison & Foerster LLP

20100286147 - Fungicidal amides: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100286149 - Novel benzamide derivatives useful as potassium channel modulators: This invention relates to novel benzamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100286148 - Pyridine compound, pesticidal composition and method of controlling pest: A pyridine compound represented by the following general formula (1); the pyridine compound in which R1 is a C1-C3 fluoroalkyl group or a C1-C3 fluoroalkoxy group; the pyridine compound in which R2 is a hydrogen atom; the pyridine compound in which R2 is a group represented by Q; a pesticidal... Agent: Birch Stewart Kolasch & Birch

20100286150 - Levosimendan for use in treating chronic valvular disease: A method for the treatment of chronic valvular disease (CVD) in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of levosimendan or a pharmaceutically acceptable salt thereof. Levosimendan was shown to significantly reduce mortality and to significantly improve quality of life in dogs suffering... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286151 - 1-oxa-3-azaspiro[4,5]decan--2-one derivatives for the treatment of eating disorders: m

20100286155 - Adrenocortical carcinoma treatment: A method of treating adrenocortical carcinoma with OSI-906.... Agent: Osi Pharmaceuticals, Inc.

20100286154 - Antihelmintic paste: The present invention is concerned with an anthelmintic paste in form of an aqueous suspension, comprising a veterinarily effective amount each of praziquantel and a macrocyclic lactone selected from avermectins, milbemycins and derivatives thereof; a cyclodextrin; a thickener; and water. The suspension formulations of the present invention are useful for... Agent: Novartis Animal Health US Inc.

20100286153 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Fish & Richardson P.C.

20100286152 - N-phenyl hydrazides as modulators of the ghrelin receptor: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof,... Agent: Glaxosmithkline Global Patents

20100286156 - Collyrium for the treatment of conical cornea with cross-linking trans-epithelial technique: A collyrium for the treatment of patients suffering from conical cornea contains a riboflavin photosensitizing substance and a surface-active agent to assist penetration of the collyrium into the corneal epithelium. The collyrium does not require removal of the corneal epithelium, with the absence of pain for the patient, who does... Agent: Kirschstein, Israel, Schiffmiller & Pieroni, P.C.

20100286157 - 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form L, methods of obtaining form L, pharmaceutical compositions comprising Form L and methods of using Form L and compositions comprising Form L.... Agent: Michael Best & Friedrich LLP

20100286158 - Dihydropyrimidinones: [

20100286159 - Pyridazines: The present invention is concerned with isoxazole-pyridazines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100286161 - Pyrazine derivatives and their use as potassium channel modulators: This invention relates to novel pyrazine derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100286160 - Substituted piperazines as cb1 antagonists: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.... Agent: Merck Patent Department (k-6-1, 1990)

20100286162 - Human papilloma virus inhibitors and pharmaceutical compositions containing same: HPV inhibitors of formula (I) in which G1 is —NHCO(CH2)n-, where n is an integer between 1 and 4, R3 is —CW(CH2)m—NR4R5 or —CW(CH2)mCH3 or —CN, where W is O, S or NH and m is an integer between 0 and 5, or R3 is one of the following groups:... Agent: Foley And Lardner LLP Suite 500

20100286163 - Indolo[3,2-c]quinoline compounds: V

20100286164 - Substituted aryl alkylamino-oxy-analogs and uses thereof: Aspects of the invention relate to substituted aryl propylamino-oxy-analogs and uses thereof. Aspects of the invention relate to compositions that are inhibitors of γ-secretase and uses thereof for treating subjects having, or at risk of developing, Alzheimer's disease.... Agent: Wolf Greenfield & Sacks, P.C.

20100286165 - Substituted oxindole compounds: p

20100286166 - Compositions for the treatment of hyperphenylalaninemia: The present invention relates to the use of specific types of compounds acting as pharmacological chaperones having a stabilizing activity on the phenylalanine hydroxylase (PAH) enzyme for the prophylaxis and/or treatment of hyperphenylalaninemia (HPA) and phenylketonuria PKU) and diseases, disorders and conditions related thereto. Further, the present invention relates to... Agent: Merchant & Gould PC

20100286167 - Dihydroxyphenyl isoindolylmethanones: e

20100286170 - (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.... Agent: Morrison & Foerster LLP

20100286169 - Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds: The present invention provides novel sulfone and sulfoxide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and methods of production are provided.... Agent: Swanson & Bratschun, L.L.C.

20100286168 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Fish & Richardson P.C.

20100286171 - Phenylacetamide derivative: A phenylacetamide derivative having sulfonyl group and cycloalkyl group on the phenyl group and having heteroaryl group on the nitrogen atom in the amide has an excellent GK activation action, thereby completing the present invention. The compound of the present invention is useful as an agent for treating diabetes, in... Agent: Fitzpatrick Cella Harper & Scinto

20100286172 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Fish & Richardson P.C.

20100286173 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent: Ostrolenk Faber Gerb & Soffen

20100286174 - Inhibiting gsnor: Treatment of myocardial infarction to reduce infarct size and organogenesis is provided by administration of agents selected from the group consisting of... Agent: Bacon & Thomas, PLLC

20100286175 - 2-(pyridin-2-yl)-pyrimidines and their use for controlling harmful fungi: In general formula (I), k represents 0, 1, 2, 3; m represents 0, 1, 2, 3, 4 or 5; n represents 1, 2, 3, 4 or 5; R1, independent of one another, represents halogen, OH, CN, NO2, C1-C4 alkyl, C1-C4 alkyl halide, C1-C4 alkoxy, C1-C4 alkoxy halide, C2-C4 alkenyl, C2-C4... Agent: Birch Stewart Kolasch & Birch

20100286176 - Flowers: The present invention relates to methods for reducing the incidence of Botrytis and improving the shelf life of flowers. In particular, the invention relates to methods for improving the vase life of cut flowers comprising the application of fungicidal compositions. The invention also relates to methods for improving the shelf... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100286177 - Bicyclic amides for the treatment of respiratory depression: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related... Agent: Coleman Sudol Sapone, P.C.

20100286178 - Compounds and uses thereof: Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, propane-1-sulfonic acid [3-(5-cyano-1H-pyrrolo [2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide, N-[3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide, pyrrolidine-1-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, N,N-dimethylamino-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives... Agent: Foley & Lardner LLP

20100286179 - Egfr polymorphisms predict gender-related treatment: The invention provides compositions and methods for identifying a gender-specific cancer patient suitable for treatment with various treatment regimens available to cancer patients. After determining if a patient is suitable for therapy, the invention also provides methods for treating these patients.... Agent: Foley & Lardner LLP

20100286182 - Hydrazide compounds as thyroid hormone receptor modulators and uses thereof: e

20100286180 - Methods of use of cyclopamine analogs: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:... Agent: Morrison & Foerster LLP

20100286181 - Pyrrole derivatives with antibacterial activity: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20100286183 - Spirohydantoin compounds and methods for the modulation of chemokine receptor activity: m

20100286184 - Aqueous solution of conophylline and/or conophyllidine: It has been found that conophylline and/or conophyllidine can be efficiently extracted from a plant producing conophylline and/or conophyllidine with an acidic aqueous solution having a pH equal to or less than 4. The extract thus obtained, i.e., aqueous solution of conophylline, and/or conophyllidine is useful for production of, for... Agent: Clark & Elbing LLP

20100286185 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck

20100286186 - Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof: The present invention concerns dicarboxylic acid linked amino acid and peptide prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, decreasing the adverse GI side effects of the opioid analgesic and increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are also... Agent: Mcdermott Will & Emery LLP

20100286187 - Method of predicting survival of a non-small-cell lung cancer patient to a chemotherapeutic treatment: Method for predicting the survival of a patient suffering from NSCLC to an antimicrotubule agent based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding CHFR in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100286188 - Means for improving cognitive functions and memory based on hydrogenated pyrido(4,3-b)indoles (variants), pharmacological means based thereon and method for the use thereof: A means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), a pharmacological means based thereon and a method for the use thereof relate to the use of chemical compounds in the field of medicine and may be used to extend the arsenal of means which... Agent: Morrison & Foerster LLP

20100286189 - (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor: An (aza)indole derivative substituted in position 5, of formula (I) in which X, Y, Z, G1, G2, G3, R1, W, and R2 have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100286190 - Certain substituted ureas, as modulators of kinase activity: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100286191 - 2-arylthiazole derivatives as cxcr3 receptor modulators: The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.... Agent: Merck

20100286192 - Non-nucleoside reverse transcriptase inhibitors: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R1, R2, R4, R5, R6, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis... Agent: Merck

20100286194 - Method for treating addiction: A method for treating addiction, in particular nicotine addiction, alcohol addiction and drug addiction, such as opioid addiction. The invention furthermore relates to novel pharmaceutical compositions for the treatment of addiction comprising a therapeutically effective amount of a compound of formula I.... Agent: Birch Stewart Kolasch & Birch

20100286193 - Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: m

20100286195 - Novel benzooxazol-and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20100286197 - Carboxamide derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20100286196 - New inhibitor of dd-peptidase and its use as antibiotic or anticancer drug: A new compound is revealed and the strain of Streptomyces sp. producing it, which may be used in the production of drugs (Formula I).... Agent: Cooper & Dunham, LLP

20100286198 - Biofilm-inhibiting effect and anti-infective activity of n,c- linked arylisoquinolines and the use thereof: n

20100286199 - Novel fungicides: Fungicidal compounds of the general formula (I), wherein the substituents are as defined in claim 1.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100286200 - Combination of metformin and an mtp inhibitor: The present invention relates to a combination of the anti-diabetic drug metformin and the MTP (microsomal triglyceride transfer protein) inhibitor (+)-phenyl-(4-{4-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester and the use thereof for combined administration in the treatment or prevention of diabetes mellitus type 2 conditions. The invention further relates to products containing as... Agent: Philip S. Johnson Johnson & Johnson

20100286201 - Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine: New polymorphic forms of (S)-2-((4-benzofuranyl)carbonylamino methyl)-1-((4-(2-methyl-5-(4-fluorophenyl))thiazolyl)carbonyl)piperidine, methods for their preparation and use in medicine.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100286202 - New compounds: w

20100286203 - Pharmaceutically acceptable salts of 2--2h-indazole-7-carboxamide: The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of... Agent: Merck

20100286204 - Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase: e

20100286205 - Wound care formulation: A gel formulation for use in filling a wound cavity and delivering active ingredient thereto, having a pH range of 6.5 to 7.5, low bioadhesive strength and cohesive integrity and being a PVA borate gel including an active ingredient and a modulator to bind borate and/or PVA in aqueous solution... Agent: Monahan & Moses, LLC

20100286206 - 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones: wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype... Agent: Gardner Groff Greenwald & Villanueva. PC

20100286207 - Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same: The present invention is related to new 2-oxo-cyclic compound, the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout,... Agent: Hogan Lovells US LLPIPGroup, Columbia Square

20100286208 - Novel polymorph of esomeprazole potassium and process for its preparation: Disclosed is a novel potassium salt of esomeprazole in polymorph form X, which can be used in pharmaceutical compositions. Processes for preparing polymorph form X of esomeprazole potassium are also provided.... Agent: M. Carmen & Associates, PLLC

20100286209 - Vinyl indazolyl compounds: The present invention provides vinyl indazolyl compounds useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100286210 - Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof: (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C1-C10 alkylene group whose... Agent: Osha Liang L.L.P.

20100286211 - Oxazolidinone derivatives as antimicrobials: The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including... Agent: Ranbaxy Inc.

20100286212 - Treating and preventing viral infections: Compounds that are useful in treating or preventing viral infections, such as influenza, are described herein. Further described are compositions made from these compounds and methods for using the compounds and their compositions in treating or preventing viral infections.... Agent: Mckeon Meunier Carlin & Curfman LLC

20100286213 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100286214 - Tricyclic compounds, compositions and methods: e

20100286215 - Bis-aromatic compounds useful in the treatment of inflammation: There is provided compounds of formula (I): wherein Y, ring A, D1, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or... Agent: K&l Gates LLP

20100286216 - Composition having a high osmotic activity and exhibiting antimicrobial, anti-inflammatory, and regenerative effects: e

20100286218 - Liquid preservative compositions: A liquid preservative composition comprises (a) an alkanol fatty monoester; and (b) an aqueous isothiazolinone solution, an alkanol-substituted aromatic compound, or a combination thereof; and is free from formaldehyde, formaldehyde-releasing compounds, and paraben compounds. Preferred compositions comprise glyceryl caprylate, together with either phenethyl alcohol or an aqueous 2-methyl-4-isothiazolin-3-one solution.... Agent: Olson & Cepuritis, Ltd.

20100286217 - Stable, low voc, low viscous biocidal formulations and method of making such formulations: A stable, low VOC, low viscosity biocide formulation comprising an effective amount of at least one biocide, and a alkyl poly glycol liquid carrier of formula (I): R—O-(AO)n—H, wherein R is a C1-C3 alkyl; AO is an ethyleneoxide group, a propy-leneoxide group, a butyleneoxide group, or a block or random... Agent: The Dow Chemical Company

20100286219 - 1, 3-dihydroimidazoles for treating cardiovascular disorders: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X signifies CH2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that... Agent: Conley Rose, P.C.

20100286220 - Hnf4alpha antagonists and methods of use: Disclosed are methods and compositions relating to antagonists of HNF4α.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100286221 - Fungicide n-cycloalkyl-benzyl-amide derivatives: The present invention relates to N-cycloalkyl-benzyl-amide derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or... Agent: Ostrolenk Faber Gerb & Soffen

20100286222 - Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors: The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The... Agent: Weaver Austin Villeneuve & Sampson LLP

20100286223 - Condensed heterocyclic pyrazole derivatives as kinase inhibitors: Bicyclo-pyrazole compound of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, processes for their preparation, combinatorial libraries comprising a plurality of them and pharmaceutical compositions thereof, are herewith disclosed: the compounds of the invention are useful, in therapy, as protein kinase inhibitors, for instance in the... Agent: Scully Scott Murphy & Presser, PC

20100286224 - Method of treating airway diseases with beta-adrenergic inverse agonists: The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat... Agent: Catalyst Law Group, Apc

20100286225 - Diazeniumdiolate compounds, a process for their preparation and pharmaceutical compositions containing them.: e

20100286226 - Combination therapy related to serotonin dual action compounds: The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor that binds to an ailosteric site of the serotonin transporter. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100286227 - Compounds from mycelium of antrodia cinnamomea and use thereof: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.... Agent: Wpat, PC Intellectual Property Attorneys

20100286254 - Crystalline forms of dmxaa sodium salt: The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100286256 - Compositions and methods for therapy for diseases characterized by defective chloride transport: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally... Agent: Seed Intellectual Property Law Group PLLC

20100286255 - Method for extracting secoisolariciresinol and dihydroquercetin from wood: The invention relates to extracting secoisolariciresinol and dihydroquercetin from wood. The inventive method consists in extracting disintegrating wood of a screen area by means of a non-splitting mixture of organic solvent and water, the solvent content ranging from 50 to 75%, in such a way that a secoisolariciresinol and dihydroquercetin-containing... Agent: K&l Gates LLP

20100286257 - Methods of use of nitroalkane compositions in dermatologic applications to prevent or treat skin aging: Topical compositions comprising an effective amount of a nitroalkene and a carrier are used to prevent or treat skin aging.... Agent: St. Onge Steward Johnston & Reens, LLC

20100286258 - Process: p

20100286259 - Epoxy-guaiane derivatives and treatment of cancer: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the... Agent: Leydig, Voit & Mayer, Ltd.

20100286260 - Milnacipran formulations: The present invention provides formulations comprising milnacipran or pharmaceutically acceptable salts thereof (e.g., milnacipran hydrochloride), including immediate release formulations and modified formulations, such as delayed release and extended release formulations. The present invention provides formulations with improved stability and high bioavailability. Processes for preparing the formulations as well as methods... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100286261 - Substituted n-acyl homoserine lactones: The substituted N-acyl homoserine lactones have the formula (I) wherein R is a saturated or unsaturated straight chain or branched chain aliphatic hydrocarbyl group containing from 5 to 14 carbon atoms; R2 is H or a 1-4C alkyl group; R3 is H or F; and any enantiomer thereof. These compounds... Agent: Bozicevic, Field & Francis LLP

20100286262 - Ptgs2 haplotypes: It has been demonstrated that a group of single nucleotide polymorphisms can be used to determine the presence or absence of certain extended PTGS2 haplotypes in the genome of a subject or individual, in order to determine the susceptibility to disease of the subject, the disease prognosis of the subject,... Agent: Michael Best & Friedrich LLP

20100286263 - Gallium complexes with polyalcohols and methods of use: Provided are complexes of gallium and polyalcohols. Also provided are pharmaceutical compositions comprising such complexes and methods of their use. Methods of preparing the complexes are also provided.... Agent: Owen J. Bates

20100286264 - Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain: The present invention relates to compositions comprising a nitric oxide releasing paracetamol and an anticonvulsant drug. The compositions of the invention can be used use in the treatment of neuropathic pain in particular diabetic neuropathic pain, painful post-infarct syndrome, pain caused by chemotherapeutic treatment or pain arising from infections by... Agent: Arent Fox LLP

20100286265 - Alpha-cyano-4-fluoro-3-phenoxybenzyl meta-halo pyrethrate, a process for preparing the same and the uses thereof: The present invention relates to a compound of formula (I), stereoisomers thereof or the mixture of these stereoisomers, wherein: X represents a halogen atom, i.e. F, Cl, Br. The present invention also relates to a process for preparing the compound, and to a use of the compound in the preparation... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100286266 - Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising... Agent: Swanson & Bratschun, L.L.C.

20100286267 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. The agent is a compound of Formula (I): wherein m is 0, 1, 2, 3, 4, 5, 6, 7 or 8;... Agent: Wellstat Management Company. LLC

20100286268 - Topical composition: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac diethylammonium salt in unusually high amounts. Said compositions represent opaque emulsion-gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and high pain relief.... Agent: Novartis Consumer Health, Inc.

20100286269 - Medium-chain length fatty acids and glycerides as nephroprotection agents: Use of medium-chain length fatty acids such as capric acid, caprylic acid or lauric acid and their salts or mono- or di- or triglycerides as nephroprotection agents to protect against renal failure progression in chronic kidney diseases This includes the treatment of kidney diseases associated with nephrectomy, renal fibrosis, glomerular... Agent: Clark & Elbing LLP

20100286270 - Compositions for the treatment of hoof diseases: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and... Agent: Hovey Williams LLP

20100286272 - Methods of use of nitroalkene compositions in dermatologic applications: Topical compositions comprising an effective amount of a nitroalkene and a carrier are used to prevent skin conditions or damage and to treat skin conditions and damage including rosacea, eczema, psoriasis, xerosis, dermatitis, seborrhea, thermal and radiation burns (including sunburn), acne, alopecia, skin aging, scars, and skin inflammation.... Agent: St. Onge Steward Johnston & Reens, LLC

20100286271 - Nitro-alkyl compound compositions: Topical compositions to improve skin condition comprise an effective amount of a nitroalkene and a non-polar carrier. Preferred nitroalkenes are nitro-linoleic acid or nitro-oleic acid.... Agent: St. Onge Steward Johnston & Reens, LLC

20100286273 - Food supplement: The present invention relates to the use of leucine, isoleucine and valine in the manufacture of a food supplement for improving the cognitive ability of a companion animal, a pet food supplement comprising leucine, isoleucine and valine and a method of improving the cognitive ability of an animal especially a... Agent: Woodcock Washburn LLP

20100286274 - Methods of diagnosing, monitoring and treating pulmonary diseases: The invention includes methods of discriminating asthma from obstructive pulmonary disease, of treating pulmonary diseases, of treating cough, of assessing the efficacy of a treatment for an obstructive pulmonary disease, and of inhibiting activation of a P2-purinoreceptor (P2R).... Agent: Fish & Richardson P.C.

20100286275 - Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100286276 - Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof: The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health.... Agent: Nixon & Vanderhye, PC

20100286277 - Method to enhance aqueous solubility of poorly soluble actives: A method to enhance solubility of an active compound comprises combining an active compound, having an aqueous solubility that is less than or equal to about 10 mg/mL, and an amount of methoxypolyethylene glycol that is sufficient to increase the aqueous solubility of the active compound. Enhancement of aqueous solubility... Agent: The Dow Chemical Company

20100286278 - Composition comprising an hdac inhibitor in combination with a retinoid: The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular... Agent: Nixon & Vanderhye, PC

20100286279 - Methods of synthesis of certain hydroxamic acid compounds: The present invention pertains to the general field of chemical synthesis, and more particularly to methods for the synthesis of certain hydroxamic acid compounds, and in particular, (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, also known as PXD101 and Belinostat®, comprising, for example, the steps of: (SAF) sulfonamide formation; (PURC) optional purification; (AAA) alkenyl-acid addition, comprising:... Agent: Swanson & Bratschun, L.L.C.

20100286280 - Inhibitors of eppin/semenogelin binding as male contraceptives: Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. The compounds described herein inhibit Eppin-semenogelin binding, and inhibit forward motility of sperm in humans and other primates. The assays identify compounds which both inhibit... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100286281 - Methods and materials for the treatment of testosterone deficiency in men: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.... Agent: Howrey LLP - East

20100286282 - Exo-s-mecamylamine formulation and use in treatment: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100286283 - Microtubule-disruptng agent and cancer cell proliferation inhibitor containing the same: The present invention provides a novel microtubule-disrupting agent, and also provides a use of the microtubule-disrupting agent. A microtubule-disrupting agent containing an α,β-unsaturated carbonyl compound as an active ingredient is provided. Further, a cancer cell proliferation inhibitor containing the microtubule-disrupting agent is also provided. As the α,β-unsaturated carbonyl compound, 6-shogaol... Agent: Edwards Angell Palmer & Dodge LLP

20100286284 - 5-[1'-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h-cyclopropa[a]naphthalen-4-yl)-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzenedicarboxaldehyde as medicaments: The present invention relates to new compounds of formula (I) and to their use as medicaments. Preferably, the said compounds are used in the preparation of a medicament or food supplement intended for the treatment and/or prevention of ailments or pathologies ensuing from a disorder of the reuptake of the... Agent: The Firm Of Hueschen And Sage

20100286285 - Pharmaceutical composition comprising oleaginous ointments and vitamin d or its derivatives in the solubilized state: The present invention relates to an anhydrous pharmaceutical composition for use in the treatment of psoriasis and other skin disorders, characterized in that it comprises an oleaginous ointment and, as active ingredient, a compound chosen from vitamin D and its derivatives, said active agent being in a solubilized form in... Agent: Buchanan, Ingersoll & Rooney PC

20100286286 - Orally disintegrating tablet: The invention provides an orally disintegrating tablet that has both adequate tablet hardness and rapid disintegrability in the oral cavity, and that undergoes minor hardness reduction and maintains good oral disintegrability even when preserved under moist conditions. In particular, the invention relates to an orally disintegrating tablet containing (a) crystalline... Agent: Leydig Voit & Mayer, Ltd

20100286288 - Quarternization of the additive amino alkylmethacrylate copolymer e for improving permeability and solubility of pharmaceuticals: The present invention relates to a strategy for improving the permeability and solubility of pharmaceuticals, based on adding a chemically modified amino alkyl methacrylate copolymer E, wherein the chemical modification is the quaternization of a fraction of the existing amino alkyl groups.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100286287 - Water-absorbing polymer structure with improved color stability: The present invention relates to a water-absorbing polymer structure comprising about 10 to about 100,000ppm, based on the solids content of the water-absorbing polymer structure, of a non-polymerized sulphonate, a non-polymerized salt of a sulphonate or a mixture of a non-polymerized sulphonate and a non-polymerized salt of a sulphonate, and... Agent: Smith Moore Leatherwood LLP

20100286289 - Chitosan-containing composition and production process of same: The present invention provides an industrially useful chitosan-containing composition in the form of any of a transparent aqueous solution, gel or dry powder having a neutral to weakly alkaline pH when in the form of an aqueous solution that can be applied to pharmaceutical additives, foods, beverages and cosmetics. A... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100286290 - Enzyme activity assay using rolling circle amplification: The present invention relates to an enzyme activity assay using rolling circle amplification for verifying that a sample contains the enzyme activity in question. Thus, the present invention pertains to a method for determining the presence or absence of one or more enzyme activities involved in circularising a non-circular oligonucleotide... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20100286291 - Multiplex detection of hepatitis virus variations: Disclosed is a method for the detection of virus variations. Disclosed also is a method for the treatment of virus infection in a subject based on the detection of virus variations. Additionally, a kit is provided for the detection of virus variations.... Agent: Morris Manning Martin LLP

  
11/04/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100279918 - Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents: A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO:... Agent: Bacon & Thomas, PLLC

20100279919 - Compositions comprising human integrin-linked kinase-sirna and methods of use thereof: The present invention provides nucleic acid molecules that inhibit ILK expression. Methods of using the nucleic acid molecules are also provided.... Agent: Seed Intellectual Property Law Group PLLC

20100279920 - Critical care product for neonatal calves: A product and method for treating dehydration in neonatal calves. The product is administered to dehydrated calves during treatment, to the exclusion of milk replacers or electrolytes.... Agent: Matthew R. Jenkins, Esq.

20100279921 - Impaired wound healing compositions and treatments: Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or... Agent: Duane Morris LLP - San Diego

20100279922 - Melanocortin receptor ligands: t

20100279924 - Peptides and peptide derivatives as well as pharmaceutical compositions containing the same: Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as... Agent: Hoffmann & Baron, LLP

20100279923 - Therapeutic application of kazal-type serine protease inhibitors: The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100279925 - Airway administration of site-inactived fviia in inflammatory conditions affecting the respiratory tract: The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of site-inactivated FVIIa or biologically active derivatives... Agent: Licata & Tyrrell P.C.

20100279926 - Compositions and methods for treating atherosclerosis: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis... Agent: Licata & Tyrrell P.C.

20100279927 - Growth factor complex: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20100279928 - Sldlr in viral hepatitis: The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100279929 - Novel bacillus thuringiensis gene with coleopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20100279930 - Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour: Analogue of human Pancreatic Polypeptide which differs from native human pancreatic polypeptide in respect of amino acid substitutions at one or more residues; and also uses of one or more of said compounds, methods that use one of more of said compounds, compositions comprising one or more of said compounds;... Agent: Nixon & Vanderhye, PC

20100279931 - Insulin derivative: The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the insulin derivatives of the invention.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100279932 - Binding constructs and methods for use thereof: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero,... Agent: Seed Intellectual Property Law Group PLLC

20100279933 - Vegf antagonist formulations: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc

20100279934 - Topical compositions for delivery of proteins and peptides: Aspects of this invention relate to compositions and methods for the stabilization, storage, and delivery of biologically active agents, in particular peptides and nucleic acids. Particularly preferred embodiments include compositions that comprise a recombinant naturally occurring human hepatocyte growth factor (HGF), such as dHGF, a five amino acid truncated HGF... Agent: Knobbe Martens Olson & Bear LLP

20100279935 - Compositions for inducing labor and associated methods: The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for... Agent: Enrique G. Estevez

20100279936 - Substituted acetylenic compounds useful for the treatment of diseases: The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C1-10heteroaryl, C6-14aryl or C6-10heterocycloalkylaryl; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C3-6 cycloalkyl, or C1-6heterocycloalkyl, each of which are optionally substituted; X represents —CR3R4—(CR5R6)n—(CR7═CR8)m—(C6-14aryl)r-(C1-10heteroaryl)s-(CR9R10)p—(CR11═CR12)q, R2 represents C1-6alkyl,... Agent: Birch Stewart Kolasch & Birch

20100279937 - Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity: Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity.... Agent: Ade & Company Inc.

20100279938 - Platelet promoting protein and the usage thereof: The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its... Agent: The Webb Law Firm, P.C.

20100279939 - Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders: The present invention provides methods of using recombinant human fibrinogen to prevent or treat excessive bleeding in pre-hospital and hospital settings. In particular, the present invention relates to methods for treating bleeding using recombinant human fibrinogen in individuals suffering from traumatic hemorrhages in pre-hospital settings and in individuals having thrombocytopenia... Agent: Fennemore Craig

20100279940 - Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof: Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100279941 - Cd36 modulation and uses thereof: Methods, uses, kits and products are described for the prevention and treatment of ischemia-associated cardiopathies such as myocardial ischemia/reperfusion (I/R) injury, based on the selective modulation of CD36.... Agent: Goudreau Gage Dubuc

20100279942 - Methods for treating motor neuron disease: An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to... Agent: Birch Stewart Kolasch & Birch

20100279943 - Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases: The present invention provides compositions for treating neurodegenerative diseases, including ALS, involving complex formation of cytosolic malate dehydrogenase with certain neurodegenerative disease-causing proteins, comprising an agent capable of reducing an interaction between a malate dehydrogenase protein and a conformationally altered or mutant protein associated with a neurodegenerative disorder, including mutant... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20100279944 - Suppression and treatment of neuropathic pain: The invention provides a method for suppressing the development of or treating neuropathic pain in a subject comprising administering to the subject an effective amount of a peptide of the formula: X1—X2—X3 (I) or X1—X2 (II) wherein X1 is an aromatic amino acid residue or is selected from the group... Agent: Kenneth Sharples

20100279945 - High-potency botulinum toxin formulations: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100279946 - Use of an active principle from flax for use in a composition for activating cytochrome c: The present invention concerns the use, in a cosmetic composition, of an effective quantity of active principle originating from flax (genus Linum) to activate cytochrome c and to stimulate the functions of the mitochondria. The active principle originates from the hydrolysis of flax proteins and contains principally polypeptides or peptides.... Agent: Young & Thompson

20100279948 - Epigenetic modifications at tnfalpha as biomarkers for sensitivity to smac mimetic-induced apoptosis: The invention provides a method for determining sensitivity of a cell population to apoptosis induced by Smac mimetics as a single agent or in combination with other chemodrugs, which method comprises assaying for an epigenetic modification at the TNFα locus in the cell population as compared to the TNFα locus... Agent: Richard Aron Osman

20100279947 - Modifications of apoptin: Phosphorylated Apoptin is described. Apoptin is tumor-specifically phosphorylated and part of the Apoptin apoptotic pathway in tumor cells is elucidated. New therapeutic possibilities, for example, novel therapeutic compounds that can work alone or, sequentially to, or jointly with other known compounds. Also, the use of tumor-specifically phosphorylation of Apoptin for... Agent: Traskbritt, P.C.

20100279950 - Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods: Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.... Agent: Leydig, Voit & Mayer, Ltd.

20100279949 - Process for preparing recombinant heterocarpine: A process for preparing recombinant heterocarpine with the complete sequence of heterocarpine (SEQ. ID. NO. 10), expression vectors comprising a polynucleotide encoding for heterocarpine, host cells transformed or transfected by said expression vectors as well as a process for obtaining heterocarpine by means of said transformed or transfected host cells... Agent: Hunton & Williams LLP Intellectual Property Department

20100279951 - Method of treating allergic conjunctivitis with cyclosporin compositions: Disclosed herein is a method of treating allergic conjunctivitis, the method comprising the step of topically administering to an eye affected with such a condition a composition comprising cyclosporin, at a concentration between about 0.001% (w/v) to about 0.01% (w/v).... Agent: Allergan, Inc.

20100279952 - Cross-linked hydrogel containing an active substance: The invention relates to a biocompatible metastable intermediate material for controlling the mobility of at least one biologically active substance. An example of the invention is a hydrogel formed by cross-linked sodium hyaluronate treated with an oxidizing agent so as to open sugar rings and form aldehyde groups. The gel... Agent: Birch Stewart Kolasch & Birch

20100279953 - Non-protein stabilized clostridial toxin pharmaceutical compositions: A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a... Agent: Allergan, Inc.

20100279954 - Method for treating celiac disease: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be... Agent: Cooley LLP Attn: Patent Group

20100279955 - Novel lipid tripeptide-based hydrogelator and hydrogel: R2, R3 and R4 independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atom(s) which may have a branched chain having 1 or 2 carbon atom(s), a phenylmethyl group or a —(CH2)n—X group, and at least one of R2, R3 and R4 represents a —(CH2)n—X group;... Agent: Oliff & Berridge, PLC

20100279956 - Biomarkers for fatty liver disease and methods using the same: The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods... Agent: Brinks, Hofer, Gilson & Lione

20100279960 - Biotinylated hexadecasaccharides, preparation and use thereof: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation;... Agent: Scully, Scott, Murphy & Presser, P.C.

20100279958 - Compounds and methods for inhibiting selectin-mediated function: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids,... Agent: Seed Intellectual Property Law Group PLLC

20100279959 - Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100279957 - Predicting responsiveness to cancer therapeutics: Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with... Agent: Michael Best & Friedrich LLP

20100279962 - Monosebacate of pyrazole derivative: The present invention provides a novel form of 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide with improved storage stability. Since bis[3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide] monosebacate has extremely excellent storage stability, it is useful as a drug substance. Furthermore, it shows an extremely good crystalline property and can be purified by a convenient method, and therefore is suitable for the... Agent: Sughrue Mion, PLLC

20100279961 - Pharmaceutical composition having a trihydroxy-chromenone derivative: The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.... Agent: Mayer & Williams PC

20100279964 - Angular pyranocoumarins, process for preparation and uses thereof: The present invention relates to methods of using 3′,4′-aromatic acyloxy substituted 7,8-pyranocoumarins compounds in reversing P-glycoprotein overexpression mediated multidrug resistance in cancer cells including uses in treating cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100279963 - Dicarbonyl derivatives and methods of use: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.... Agent: Leydig Voit & Mayer, Ltd

20100279965 - Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors: Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are... Agent: Seed Intellectual Property Law Group PLLC

20100279966 - Compositions and methods for treating cancer: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20100279967 - Compositions and methods for treating cancer: Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20100280099 - Combination treatment for the treatment of hepatitis c virus infection: The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100280094 - Compositions and methods to treat muscular & cardiovascular disorders: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100280097 - Compositions comprising hif-1 alpha sirna and methods of use thereof: The present invention provides nucleic acid molecules that inhibit HIF-1α expression. Methods of using the nucleic acid molecules are also provided.... Agent: Seed Intellectual Property Law Group PLLC

20100280102 - Double-stranded ribonucleic acid with increased effectiveness in an organism: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang... Agent: Nixon Peabody LLP

20100280101 - Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method: The present invention provides a method of inhibiting cancer cell proliferation by suppressing a function of ZNF143, a cancer cell proliferation inhibitor containing as an active ingredient a substance capable of inhibiting a function of ZNF143, like a ZNF143-specific siRNA, a prophylactic and/or therapeutic drug for cancer, a method of... Agent: Leydig Voit & Mayer, Ltd

20100280103 - Methods and compositions for acid phosphatase-1 gene inhibition: The ACP1 *A allele provides a means for diagnosing susceptibility of a human subject to hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome, a means for treating, or preventing the onset of, hyperlipidemia and metabolic syndrome, and a means for screening and identifying drugs suitable for use in treating or preventing... Agent: Themis Law

20100280098 - Receptor targeted oligonucleotides: Disclosed herein are oligonucleotide conjugates that include ligands that target cell receptors that mediate endocytosis. The ligands can include peptides and small molecules. The conjugates can include carrier macromolecules to which the ligands and oligonucleotides are attached, or conjugates where an oligonucleotide is attached to a ligand in the absence... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100280095 - Therapeutic agent for wounds and screening method for the same: The present invention provides an agent for treating wound, containing a substance that suppresses the expression or function of PDLIM2. The substance that suppresses the expression or function of PDLIM2 is preferably an siRNA or antisense nucleic acid capable of specifically suppressing the expression of PDLIM2, or an expression vector... Agent: Leydig Voit & Mayer, Ltd

20100280100 - Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hemoglobin (HBF/HBG), in particular, by targeting natural antisense polynucleotides of Hemoglobin (HBF/HBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression... Agent: Curna

20100280096 - Treatment of influenza: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense... Agent: Sughrue Mion, PLLC

20100280105 - Detection of mage-a expression: An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100280104 - Methods and kits for diagnosis and treatment of cell-cell junction related disorders: We have discovered that loss of Filamin A function results in weakened cell-cell junctions and vascular defects in genetically engineered mice. In addition, we have shown that patients with mutations in the gene coding for Filamin A exhibit high rates of cardiovascular disorders. On the basis of this discovery, the... Agent: Clark & Elbing LLP

20100279969 - Azido purine nucleosides for treatment of viral infections: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds... Agent: Intellectual Property / Technology Law

20100279968 - Mutagenic nucleoside analogs for the treatment of viral disease: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.... Agent: Townsend And Townsend And Crew, LLP

20100279971 - Antifolate compounds for the treatment of melanoma: This invention relates to compounds of the formula X) or XI) (X) (XI) wherein: each —R1, —R2 and —R3 is independently -Q1, —OH or —H, where at least one of —R1, —R2 and —R3 is not —H or —OH; each —R4 and —R5 is independently -Q2 or —H; each -Q1... Agent: Mcdermott Will & Emery

20100279970 - Method of reducing intraocular pressure in humans: Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100279972 - Composition for external application: A composition for external use capable of more efficiently deriving the effect of purine substances (and/or salts thereof) including (A) sugar; and (B) at least one member selected from the group consisting of purine substances and salts thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100279973 - Synthesis of purine nucleosides: A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.... Agent: Merchant & Gould PC

20100279975 - Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells: The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the... Agent: Howrey LLP-ca

20100279974 - Nucleosides with non-natural bases as anti-viral agents: A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.... Agent: Jones Day

20100279976 - Use of artemisinin and its derivatives in cancer therapy: A method for treating cancer in a mammal includes administering to the mammal in need thereof a therapeutically effective amount of artemisinin (ART) or its derivative, such as dihydroartemisinin (DHA), artemether (ARM), or artesunate (ARS) alone or in combination with a chemotherapeutic agent, such as gemcitabine and carboplatin. A method... Agent: Osha Liang L.L.P.

20100279977 - Compositions and methods for treating cancer: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20100279978 - Methods of reducing the severity of mucositis: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.... Agent: Mccarter & English, LLP & Eisai Co.

20100279979 - Immunopotentiating agent for use in animals: A simplified method for producing an immunopotentiating agent from cell walls of yeast, other fungi or bacteria is provided and its use as an additive to animal feed to increase resistance to various infections and to potentiate the effect of vaccines is described.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper LLP(us)

20100279980 - Moenomycin biosynthesis-related compositions and methods of use thereof: The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression... Agent: Foley & Lardner LLP

20100279981 - Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid: e

20100279982 - Cellulose derivative:

20100279983 - Novel inhibitors of beta-lactamase: This invention provides novel β-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of β-lactamases and synergize the antibacterial effects of β-lactam antibiotics (e.g., imipenem and ceftazidime) against those micro-organisms normally resistant to the β-lactam antibiotics as a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100279984 - Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin: The present invention relates to pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of analgesic acting substances, especially pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents selected from the group consisting of gabapentin, pregabalin, XP13512, carbamacepin, amitryptilin, ketorolac, diclofenac,... Agent: Millen, White, Zelano & Branigan, P.C.

20100279985 - Liver function-protecting agent: Disclosed is a liver function-protecting agent which comprises a phospholipid as an active ingredient, and which can exhibit an excellent prophylactic and ameliorating effect on the deterioration in the liver function when ingested orally. Also disclosed is a liver function-protecting food, beverage or feed. The phospholipid is preferably one derived... Agent: Greenblum & Bernstein, P.L.C

20100279986 - Heterocyclic derived metalloprotease inhibitors: s

20100279987 - Compositions containing chalcones and use thereof: The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp.... Agent: Philip S. Johnson Johnson & Johnson

20100279989 - Oral contraception with trimegestone: The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100279988 - Transdermal delivery system for hormones and steroids: A transdermal delivery system comprising a composition comprising a pharmacological agent and a penetration enhancer wherein the penetration enhancer comprises polyethylene glycol (PEG) of average molecular weight no more than 300.... Agent: Foley And Lardner LLP Suite 500

20100279990 - Antiproliferative compounds, compositions and methods of use: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100279991 - Tetrahydro-cyclopentyl pyrazole cannabinoid modulators: e

20100279992 - Use of lanostane and poria extract in treating cachexia: A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60%... Agent: Occhiuti Rohlicek & Tsao, LLP

20100279993 - Pharmaceutical propylene glycol solvate compositions: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.... Agent: Frank C. Eisenschenk , Ph.d. Saliwanchik , Lloyd & Saliwanchik

20100279994 - Ansamycin formulations and methods of use thereof: The present invention provides pharmaceutical compositions of reduced forms of benzoquinone-containing ansamycins, and salts thereof. The present invention also relates to the use of said pharmaceutical compositions in methods of treating and modulating disorders associated with hyperproliferation, such as cancer.... Agent: Foley Hoag, LLP (w/ipx)

20100279995 - Novel ansamycin derivatives: There are provided inter alia derivatives of a benzenoid ansamycin which contain a 1,4-dihydroxyphenyl moiety bearing at position 6 an amino carboxy substituent, in which position 2 and the carboxy substituent at position 6 are connected by an aliphatic chain of varying length characterised in that one or both of... Agent: Dann, Dorfman, Herrell & Skillman

20100279997 - Analgesic that binds filamin a: A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula A, wherein A, B, X, R1, R2, R7 and R8, and the dashed lines are defined within.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100279996 - Novel analgesic that binds filamin a: A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R1 and R2 are substituents, and W is a ring structure that are defined within.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100279998 - Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors: The present invention relates to piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100280000 - Therapeutic agents 713: e

20100279999 - Insecticidal compounds: A compound of formula (I), wherein A1, A2, A3, A4, G1, L, R1, R2, R3, R4, Y1, Y2 and Y3 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100280002 - Aminopyridine-derivatives as inductible no-synthase inhibitors: c

20100280001 - Imidazoquinolines with immuno-modulating properties:

20100280003 - Combinations of jak inhibitors:

20100280004 - Small molecule correctors of deltaf508 cftr trafficking: This invention provides compounds of Formula I. The compounds are correctors of ΔF508 CFTR trafficking. Also provided are uses of compounds of Formula I for treatment, as well as methods of treatment, of cystic fibrosis.... Agent: Fenwick & West LLP

20100280005 - Renin inhibitors: Disclosed are compounds of Formula I, wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100280006 - 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or... Agent: Novartis Institutes For Biomedical Research, Inc.

20100280008 - Aurora kinase modulators and method of use: wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase... Agent: Amgen Inc.

20100280007 - Pyridazinone derivatives: The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.... Agent: Ross J. Oehler Cephalon, Inc.

20100280009 - 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds... Agent: Merck

20100280012 - Azaazulene compounds: An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof... Agent: Lowe Hauptman Ham & Berner, LLP

20100280013 - Carbinol derivatives having heterocyclic linker: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100280010 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Global Patents

20100280011 - Dual mechanism inhibitors for the treatment of disease: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One... Agent: Michael Best & Friedrich LLP

20100280014 - N-phenyl- (piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor: o

20100280015 - Noval 1,4-diaza-biclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20100280016 - Pyrazoline compounds: e

20100280017 - Combination of selected analgesics and cox-ii inhibitors: Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.... Agent: Crowell & Moring LLP Intellectual Property Group

20100280018 - Derivatives of hydroxamic acid as metalloproteinase inhibitors: m

20100280019 - Isoxazoles: wherein X, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100280020 - Isoxazoles: wherein X, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100280021 - Pyridopyrimidine protein tyrosine phosphatase inhibitors: e

20100280022 - Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type: wherein: X represents a hydrogen or halogen atom or a hydroxy function, R1 represents: a 1-piperazinyl radical, which may be substituted in position 4 by a methyl, acetyl or 4-aminobenzyl group; a morpholino radical: a 1-pyrrolidinyl radical substituted in position 3 by a chlorine atom or by an amino, aminomethyl,... Agent: Ip Group Of Dla Piper LLP (us)

20100280025 - Equilibrative nucleoside transporter ent1 inhibitors: The present invention is related to novel compounds of formula (I) having equilibrative nucleoside transporter ENT1 inhibiting properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the inhibition of ENT1 receptors in animals, in particular humans.... Agent: Philip S. Johnson Johnson & Johnson

20100280024 - Renin inhibitors: The present invention relates to renin inhibitors of formula (I), their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in... Agent: Ladas & Parry LLP

20100280023 - Thiazole derivatives: It is intended to provide an adenosine A2A receptor antagonist containing as an active ingredient a thiazole derivative represented by the general formula (I) [in the formula, R1 represents a substituted or unsubstituted five-membered aromatic heterocyclic group containing at least one oxygen atom, R2 represents a substituted or unsubstituted heterocyclic... Agent: Fitzpatrick Cella Harper & Scinto

20100280026 - Compositions useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders.... Agent: Ropes & Gray LLP

20100280027 - Pharmaceutical compounds: Provided herein are methods of treating diseases or disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, which method includes administering to a patient in need thereof a compound that is a fused pyrimidine of formula (I):... Agent: Viksnins Harris & Padys Pllp

20100280028 - Cxcr3 receptor antagonists: and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100280029 - Novel compounds: d

20100280030 - 2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumours: Compounds of the formula (I), in which R1, R2, R3, R3′, R4, R4′, E, E′, E″ and E′″ have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100280031 - Lipid formulation of apoptosis promoter: An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof... Agent: Harness Dickey & Pierce, PLC

20100280032 - Method for treating inflammatory disorders: The present invention relates to a method for suppressing the immune system in a subject in need thereof, and a method for treating an inflammatory or immune disorder in a subject in need thereof.... Agent: Foley & Lardner LLP

20100280033 - Pyrazole derivatives: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrazole compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100280034 - Modulation of pathogenicity: e

20100280035 - Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier: The present invention concerns pharmaceutical compositions comprising the pH dependent drug compound 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier.... Agent: Novartis Corporate Intellectual Property

20100280037 - Crystalline form of a dihydropteridione derivative: The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100280038 - Methods of treatment of chronic pain using eszopiclone: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20100280036 - Modulation of pathogenicity: e

20100280039 - Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments:

20100280041 - Rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction of pulmodil and pulmodil-1: A pharmaceutical composition for treating one of a cardiovascular disease and a pulmonary artery disease, comprising one of a first compound having a Formula I and a second compound having a Formula II.... Agent: Volpe And Koenig, P.C.

20100280040 - Synthesis and pharmacokinetic activities of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives: A compound including a salt derivative of the chlorophenylpiperazine moiety is provided, wherein the chlorophenylpiperazine moiety is derived from the reaction of a xanthine and a piperazine. The salt derivative thereof is non-toxic to the tracheal smooth muscle cells (TSMCs) and can be intravenously-, orally- or sublingually-dosed into the mammals.... Agent: Volpe And Koenig, P.C.

20100280042 - Quinazoline derivatives for the treatment of tumours: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive... Agent: Morgan Lewis & Bockius LLP

20100280043 - Pyrazolopyridines as kinase inhibitors: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Viksnins Harris & Padys Pllp

20100280044 - Enhanced erythropoiesis and iron metabolism: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.... Agent: Fibrogen, Inc.

20100280045 - Novel compounds: e

20100280046 - Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions: Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce testosterone synthesis and for the treatment of prostate cancer, benign prostatic hyperplasia, seborrhea, hirsutism, alopecia, polycystic ovary syndrome, and other diseases and... Agent: Cantor Colburn, LLP

20100280047 - Salts of active ingredients with polymeric counter-ions: Polymeric water-soluble salts of medicaments that are sparingly soluble in water, consisting of a polymer with anion character that is soluble in water at pH values of 2-13 and a sparingly soluble medicament with cation character.... Agent: Connolly Bove Lodge & Hutz, LLP

20100280049 - Antagonists of pgd2 receptors: Described herein are compounds and pharmaceutical compositions containing such compounds that antagonize the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 antagonists, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated... Agent: Wilson, Sonsini, Goodrich & Rosati

20100280048 - Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase: The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.... Agent: Astrazeneca R&d Boston

20100280050 - Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis: The invention provides a method of treating or preventing fibrosis in a subject by administering a 5-HT modulator, e.g., a 5-HT2B modulator. In particular embodiments, the 5-HT modulator is a piperidinylamino-thieno[2,3-d]pyrimidine compound.... Agent: Goodwin Procter LLP Patent Administrator

20100280051 - Use of allopurinol for the treatment of hand foot skin reaction: Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase Inhibitor (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.... Agent: Cooper & Dunham, LLP

20100280052 - Use of antivirals to treat cmv-related conditions: The invention provides for the use of compounds active against cytomegalovirus (CMV) in the preparation of medicaments for improving the immune response of a CMV-seropositive, immunocompetent individual, or for the amelioration of certain other medical conditions. Suitable compounds include the nucleoside analogues acyclovir, famciclovir, and valacyclovir. Infection with cytomegalovirus is... Agent: Berliner & Associates

20100280053 - Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiodiazol-4-yl)-2,5,6-trimethyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-4-propyl-amine as a crf antagonist: The present invention relates to a novel benzothiadiazole of formula (A) in free base or acid addition salt form, its preparation, its use as pharmaceutical and pharmaceutical compositions containing the compound.... Agent: Fanelli Strain & Haag PLLC

20100280054 - Multicyclic amino acid derivatives and methods of their use: Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders:... Agent: Lexicon Pharmaceuticals, Inc.

20100280055 - Flavoring systems for pharmaceutical compositions and methods of making such compositions: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium... Agent: Paul D. Yasger Abbott Laboratories

20100280056 - Identification of subjects likely to benefit from statin therapy: Methods are provided herein to determine if a subject is a candidate for treatment with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). The method includes determining the presence of at least one polymorphism in the HMGCR gene in a sample from a subject. The presence of at least one... Agent: Klarquist Sparkman, LLP (ott-nih)

20100280057 - Novel analgesic that binds filamin a: A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R1 and R2 are substituents, and n, W, X and Y are defined within.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100280058 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Feldman Gale, P.A.

20100280059 - Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations: The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction... Agent: Foley And Lardner LLP Suite 500

20100280062 - (e)-n--methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis: The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective... Agent: Eli Lilly & Company

20100280060 - Methods of screening and compositions for life span modulators: Identification of nucleic acids involved in life span diseases and disorders or related diseases and disorders, and the use of such methods for identifying candidate agents which modulate life span diseases and disorders or related diseases and disorders are provided. Compositions and methods for treating life span diseases and disorders... Agent: Fenwick & West LLP

20100280061 - Novel analgesic that binds filamin a: A compound, composition and method are disclosed that can bind to FLNA and provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R1 and R2 are substituents on W that is a ring structure, R3 and R4 are substituents on the depicted nitrogen atom, m,... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100280063 - 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention... Agent: Genentech, Inc.

20100280064 - Pharmaceutical composition having improved storage stability: A pharmaceutical composition containing (A) a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, and (B) a water-soluble polymer. The formula (I) is as follows:... Agent: Holtz, Holtz, Goodman & Chick, PC

20100280065 - Perharidines as cdk inhibitors: p

20100280066 - Acylated amino acid amidyl pyrazoles and related compounds: This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or... Agent: Howrey LLP-ca

20100280067 - Inhibitors of acetyl-coa carboxylase: The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100280068 - Quinoline derivatives and their use as fungicides: Compounds of the general Formula (1) wherein the substituents are as defined in claim 1, are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100280069 - Controlled release local anesthetic for post dental surgery and method of use: The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically... Agent: Passe' Intellectual Property, LLC

20100280070 - Novel tetrahydroquinolines as aromatase inhibitors: The invention relates to synthesis and biological screening of novel tetrahydroquinolines of formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them for aromatase inhibition: (I). The present invention also relates to a process for the preparation of the novel tetrahydroquinolines, their derivatives, their... Agent: Jerome D. Jackson (jackson Patent Law Office)

20100280071 - Benzimidazoles which have activity at m1 receptor and their uses in medicine: e

20100280072 - 2-'4-(hydroxymethyl-phenylamino) -piperidine-1-yl!-n- (9h-carbazol-3yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity: The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. The substituents are as defined in the present claim 1.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100280073 - Tricyclic inhibitors of hydroxysteroid dehydrogenases: The present invention provides tricyclic compounds according to formula (I): (I) where R1, R2, R3, W, X, Y, Z, m, n, and p are as defined in the description; as well as pharmaceutical compositions comprising the same, methods of use of the compounds and compositions of the invention for the... Agent: Foley And Lardner LLP Suite 500

20100280074 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20100280075 - Paclitaxel enhancer compounds: e

20100280076 - Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics: in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100280077 - Process for preparation of stable amorphous r-lansoprazole: A process for preparing stable amorphous R-(+)-lansoprazole comprising optically resolving racemic lansoprazole by the formation of host-guest inclusion complexes by selectively and reversibly including chiral guest molecules in the lansoprazole.... Agent: Florek & Endres PLLC

20100280079 - 0novel, 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II... Agent: Philip S. Johnson Johnson & Johnson

20100280078 - 1-(azolin-2-yl)amino-1,2-diphenylethane compounds for combating animal pests: e

20100280080 - Medicaments: Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma.... Agent: Barnes & Thornburg LLP

20100280081 - Anti-inflammatory agents as virostatic compounds: t

20100280082 - Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators: Compounds of Formula (I) wherein R1, R2, R3 R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100280083 - Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition: or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is halo-lower alkyl, lower acyl, halo-lower alkylcarbonyl, cycloalkylcarbonyl, optionally substituted arylcarbonyl, lower alkoxycarbonyl or the like; R4 is lower alkyl, halo-lower alkyl, cycloalkyl, lower alkoxy-lower alkyl or the like, which... Agent: Sughrue Mion, PLLC

20100280084 - Cyp1b1 genotype: The invention relates to pharmacology, pharmacokinetics and toxicology, and more specifically to methods of identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It further related to the genetic basis of inter-patient variation in response to therapy, including... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100280085 - Chemical compounds: The use of a compound of formula (I) wherein X is (i), (ii) or (iii), where the substituents have the meanings assigned to them in claim 1, or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100280086 - Substituted thiophenes: Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100280087 - Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels: This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20100280088 - Halosubstituted aryloxyalkylimidazolines for use as pesticides: The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100280089 - Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases: Compositions and methods for the treatment of glaucoma and other ocular diseases are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK), such as SP600125 in the treatment of glaucoma and other ocular diseases.... Agent: Alcon

20100280090 - Tape preparation comprising etodolac in ionic liquid form: Disclosed is a tape preparation comprising etodolac in an ionic liquid form, which has high transdermal absorbability. Etodolac is reacted with an organic amine compound to produce an ionic liquid of etodolac. By using the ionic liquid, it becomes possible to increase the transdermal absorbability of etodolac. Further for the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100280091 - Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disbustituted pyran derivatives: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.... Agent: Brooks Kushman P.C.

20100280092 - N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the... Agent: Birch Stewart Kolasch & Birch

20100280093 - Process for the preparation enantiomerically pure salts of n-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine: The present invention relates to duloxetine salts having enantiomeric purity of 98% or more and a process for such salts.... Agent: Ranbaxy Inc.

20100280106 - Oral composition to reduce cold symptoms and duration of same: An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc.... Agent: Snell & Wilmer L.L.P. One Arizona Center

20100280107 - Treating benign prostate hyperplasia with sarms: This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof... Agent: Pearl Cohen Zedek Latzer, LLP

20100280108 - Antitumoral compounds: i

20100280110 - (3r)-l-menthyl 3-hydroxybutyrate, process for producing the same, and sensate composition comprising the same: The present invention provides a cooling component or sensate component which has further strong cooling intensity and is excellent in the persistency or refresh-feeling and cool-feeling, a sensate composition comprising the same, and various products comprising the sensate composition. The present invention relates to, as a cooling component or sensate... Agent: Sughrue-265550

20100280109 - Lipid compounds for use in cosmetic products, as food supplement or as a medicament: e

20100280112 - Composition enriched in diglyceride with conjugated linoleic acid: The present invention relates to an oil composition containing a large amount of a. diglyceride of conjugated linoleic acid (CLA), and more particularly to an oil composition with body weight control, anticancer, antioxidation and immune enhancement functions, which is based on a diglyceride of conjugated linoleic acid resulted from an... Agent: Fish & Richardson P.C.

20100280113 - Compositions and methods for the treatment of cystic fibrosis: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood... Agent: Ronald I. Eisenstein

20100280111 - Skin external preparations and cosmetics: e

20100280114 - Primers and primer sets for use in methods to detect the presence of acidovorax avenae subsp. citrulli: The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen Acidovorax avenae subsp. citrulli in a test sample.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20100280115 - Compositions of human lipids and methods of making and using same: The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.... Agent: Cooley LLP Attn: Patent Group

20100280116 - Linoleic acid active agents for enhancing probability of becoming pregnant: The present invention is directed to a methods and compositions for enhancing the probability that a subject will become pregnant. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a linoleic acid active agent, e.g., linoleic acid, a polyunsaturated fatty acid analog thereof, etc.... Agent: Bozicevic, Field & Francis LLP

20100280117 - Menorrhagia instrument and method for the treatment of menstrual bleeding disorders: Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders.... Agent: Davidson, Davidson & Kappel, LLC

20100280118 - Methods for treating substance dependence: The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of... Agent: The Scripps Research Institute

20100280120 - Compound inducing angiogenesis response in ischaemic tissues: This invention deals with a novel straight chain compound, namely, 1,6-diamino alkanoic acid having a straight chain of six carbon atoms with two terminal amino groups and accompanying —COOH group, which is capable of effecting controlled formation of new blood vessels in ischaemic tissues, and their pharmaceutically acceptable salts and/or... Agent: Bingham Mccutchen LLP

20100280119 - L-ornithine phenyl acetate and methods of making thereof: Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some... Agent: Knobbe Martens Olson & Bear LLP

20100280121 - Production of adapalene gels: A method for producing an adapalene aqueous gel on an industrial scale including formulating a gelling medium A by mixing water and propylene glycol and adding a gelling agent thereto; formulating an adapalene medium B by dispersing adapalene in water, in the presence of a surfactant; next adding the adapalene... Agent: Buchanan, Ingersoll & Rooney PC

20100280122 - Transdermal delivery of beneficial substances effected by a hostile biophysical environment: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may... Agent: Wolf Greenfield & Sacks, P.C.

20100280123 - Food supplement containing alpha-keto acids for supporting diabetes therapy: Food supplement containing alpha-keto acids for supporting diabetes therapy. The present invention relates to a formulation which is used as food supplement and contains alpha-keto acids for supporting therapy in diabetes mellitus type II (DM).... Agent: Smith, Gambrell & Russell

20100280124 - Acyl-urea derivatives and uses thereof: Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100280125 - Medicinal agent: Medicine and pharmacology, in particular a medicinal agent exhibiting anti-tumoral and immunomodulatory actions and including a tri-p-amino-thiphenyl-chlormethan tetramethylated, pentamethylated or hexamethylated derivative, the mixtures thereof or the combination thereof with dextrin. The agent of this invention exhibits a high activity and a reduced side effect.... Agent: Pauley Petersen & Erickson

20100280126 - Method of inhibiting inflammatory pain: A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt.... Agent: Crowell & Moring LLP Intellectual Property Group

20100280127 - Inhibiting neurotransmitter reuptake: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.... Agent: Fish & Richardson P.C.

20100280129 - Method of treating pain caused by inflammation: A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amoung of a (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound or a physiologally acceptable salt thereof, such as the hydrochloride or citrate salt.... Agent: Crowell & Moring LLP Intellectual Property Group

20100280128 - Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain: The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain.... Agent: Crowell & Moring LLP Intellectual Property Group

20100280130 - Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis: The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.... Agent: Leydig Voit & Mayer, Ltd

20100280131 - Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women: e

20100280132 - Method for modifying polyphenol containing plant materials and medical uses of modified polyphenol plant containing materials: The present invention relates to a method for modifying polyphenol containing plant material(s), wherein said method comprises: mixing at least one polyphenol containing material and at least one solvent to provide a mixture; heating the mixture to eliminate bacterial species present to provide a heated mixture; adding at least one... Agent: Knobbe Martens Olson & Bear LLP

20100280133 - Aqueous emulsion containing a cyclodextrin derivative, a perfume, and a polysorbate: Aqueous fragrance emulsions are prepared from a hydrophobic fragrance substance, a cyclodextrin derivative, and a polysorbate. The emulsions are stable despite containing a high proportion of fragrance and can be used to prepare uniform coatings on substrates.... Agent: Brooks Kushman P.C.

20100280134 - Markers for bladder cancer detection: A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is... Agent: Andrus, Sceales, Starke & Sawall, LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.35698 seconds

PATENT INFO